(19) TZZ_ _T

(11) EP 1 528 894 B1

(12) EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61B 17/58 (2006.01) 03.06.2015 Bulletin 2015/23 (86) International application number: (21) Application number: 03721928.4 PCT/US2003/013273

(22) Date of filing: 29.04.2003 (87) International publication number: WO 2003/092468 (13.11.2003 Gazette 2003/46)

(54) BIOMATRIX STRUCTURAL CONTAINMENT AND FIXATION SYSTEMS STRUKTURELLE BIOMATRIX-HALTE- UND FIXIERSYSTEME SYSTEMES DE FIXATION ET DE CONFINEMENT STRUCTURELS DE MATRICES BIOLOGIQUES

(84) Designated Contracting States: • BERG, Eric, P. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Plymouth, MN 55447 (US) HU IE IT LI LU MC NL PT RO SE SI SK TR (74) Representative: Persson, Albin (30) Priority: 29.04.2002 US 376136 P Hansson Thyresson Patentbyrå Box 73 (43) Date of publication of application: 201 20 Malmö (SE) 11.05.2005 Bulletin 2005/19 (56) References cited: (73) Proprietor: Gel-Del Technologies, Inc. EP-A1- 0 082 621 EP-A2- 0 475 077 St. Paul, MN 55108 (US) WO-A2-99/37240 DE-C1- 4 313 192 US-A- 4 787 906 US-A- 4 801 299 (72) Inventors: US-A- 5 211 664 US-A- 5 443 483 • MASTERS, David, B. US-A- 5 709 683 US-A- 6 077 076 Hastings, MN 55033 (US) US-B1- 6 248 110 US-B1- 6 371 988

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 528 894 B1

Printed by Jouve, 75001 PARIS (FR) EP 1 528 894 B1

Description

BACKGROUND OF THE INVENTION

5 [0001] Fractures are a common clinical condition. In 1997 in the United States alone, there were approximately eight million fractures. In the same time period there were more than 25 million worldwide. In the treatment of fractures more than 740,000 repair procedures were performed at US hospitals. Of the fracture repair procedures, a total of 9,110 open- reduction without internal fixation procedures were performed and a total of 468,310 open-reduction with internal fixation procedures were performed. Some key statistics that are applicable to the specific scope of the current study are those 10 related to non-unions and malunions. It has been reported that between 2-7% of fractures are nonunions. Many of the nonunion fractures occur in the tibia. The overall rate of delayed union in tibia fractures ranges from 5-61 %, and the rate for nonunions in tibial fractures vary from 0-21 %. [0002] The number of procedures that could utilize the proposed fracture fixation sleeve of the present invention includes the open-reduction procedures primarily of long bone fractures (477,420 procedures). In particular, the proce- 15 dures that utilize bone graft or orthobiologic agents (10%) would be applicable (47,720 procedures). Also of note would be the nonunion fractures (14,800 procedures). [0003] One major goal of orthopaedic surgery is to incorporate methods that will stimulate the healing of bone. Many methods of treatment yield successful results, however complications do arise. Bone grafts and synthetic materials are often applied in these circumstances. Basic science has progressed this area of orthopaedics a great deal, however a 20 continued need for quality research and new, useful products exists. The dynamic nature of bone and its ability to repair itself makes this a challenging endeavor in the orthopaedic community. [0004] Bone is a material that is characterized by cells and mineral salts embedded in a fibrous matrix. Each of the base materials of bone supply essential components of the strength which are required to maintain the overall mechanical function of osseous tissue. Among two of the key elemental materials leading to the functional strength of bone are Type 25 I collagen and hydroxyapatite (HAp). The fibrous matrix of bone is comprised primarily of collagen (90%). Type I collagen is required for the tensile strength in bone. Bones are required to maintain a significant amount of tensile strength resistance due to the bending loads that are applied during normal functioning. The strength and rigid nature of bone is due to the mineral component of the material. In bone, the mineral component consists mainly of hydroxyapatite. The combination of the basic substrates of bone leads to a material that can resist and transfer both tensile and compressive 30 loads. [0005] A fracture occurs when the forces that are applied exceed the load bearing capacity of the bone. The result is structural failure. The load applied, the direction of the load, the size and geometry of the bone, and the material properties of the bone are all factors in determining if or when a bone will fracture. Several mechanisms play a role in the healing of a bone after fracture. There are biochemical, biomechanical, cellular, hormonal, and pathological factors that influence 35 the bone healing process. [0006] The healing process of bone resembles the early stages of bone development. The injured area first goes through an inflammatory stage characterized by the migration of cells to the region and followed by an ingrowth of vascular tissue into the affected area. The next phase of fracture healing involves the development of a supportive connective tissue generated by fibroblasts. The connective tissue network supports the vascular growth into the area 40 as healing takes place. Finally, the fracture healing process is completed with the remodeling phase. The goal of the remodeling phase is to return the bone to its original shape, structure, and mechanical strength. The remodeling process is time dependent. It is characterized by a process whereby the bone reacts to the mechanical stress it is subjected to through a dynamic resorption/growth process. As a bone is mechanically loaded, it will respond by building new tissue, realigning the matrix and minerals, and resorption of bone where adequate loading is not present. In order to facilitate 45 the building of new tissue, a prosthesis containing a demineralized bone powder such as that identified in EP0082621 has been suggested. This document represents the closest prior art to the subject-matter of claim 1. There are several reasons why fractures fail to heal. Among these are: inadequate immobilization, comminuted and devascularized bone, poor vascularity, infection, prior irradiation, bony defects, systemic factors, reaction to medications, and smoking. The failure of a fracture to heal is considered a non-union or delayed union fracture. 50 [0007] Non-union or delayed-union fractures are among the most difficult to treat. Fractures that do not properly heal resulting in a delayed or nonunion may require several surgeries utilizing a variety of techniques. Surgical methods utilized in the treatment of such fractures include: plating, internal fixation, intramedullary nails, and the use of bone grafting or bone substitute materials. Failure of the surgical methods can result in [0008] This document represents the closest prior art to the subject-matter of claim 1. pseudoarthritis of the fracture 55 site, instability, loss of weight-bearing ability, and painful, device assisted ambulation. [0009] One method that is utilized extensively in the treatment of the specified fractures is the use of bone grafting or the use of bone substitutes. Materials that are used can be either osteogenic, osteoconductive, or osteoinductive. A variety of materials are used, but they can be divided into several specific groups. The generalized categories are

2 EP 1 528 894 B1

autograft, allograft, xenograft, synthetic materials, and various combinations. [0010] Despite many advances in the methods to treat these specified fractures using implanted medical devices including synthetic materials, there are still concerns with the ability of synthetic materials to integrate with the body’s tissues. The use of materials produced from the body’s own biopolymers can reduce the risk of detrimental effects and 5 increase the body’s ability to regenerate itself. Natural biomaterials have been researched, however they have not been shown to demonstrate the required physical properties required for implant systems.

SUMMARY OF THE INVENTION

10 [0011] The treatment of segmental defects, nonunion, and delayed union bone fractures remains a severe clinical problem. As one study concluded "Management of severe lower extremity fractures ...could be improved by methods that stimulate and accelerate the fracture healing process." The present invention is aimed at filling this essential clinical need. The innovation of this concept is directed both in the production of a new, biocompatible matrix material and a new application within the field of orthopedic surgery to treat these selected bone fractures. More specifically, the present 15 invention comprises a biomatrix containment and fixation system according to claim 1. In various embodiments, a containment sleeve and/or particles include a bone mending biochemical, such as hydroxyapatite into the biomatrix material comprised of proteins such as collagen and elastin and one or more biocompatibles solvents such as water. Additionally, a method for implanting and securing an implant system comprised of the biomatrix containment sleeve and particles is disclosed. 20 [0012] The long-term goal of the fracture fixation system is to enable bone to heal across defects through osteocon- ductive regeneration directed and contained by a biomatrix sleeve and induced by biomatrix particles administered into the defect. This technology offers a new and simplified treatment method for fractures that are exceptionally difficult to treat and a basis to develop these products. [0013] Furthermore, embodiments of the present invention improve local anesthetic blockade of peripheral nerves by 25 using a biocompatible protein matrix drug delivery system. Other embodiments of the present invention also stimulate peripheral nerve response due to the implanted local anesthetic thereby reducing acute pain. The effects of prolonged local anesthetic block have been determined, in vivo. It was found that protein biomatrices of the present invention can be utilized to deliver local anesthetic agents to create nerve block for days to weeks and that the underlying pain mediating biochemicals couldbe altered by this treatment, suggesting thatprolonged nerve block canalter chronic pain mechanisms. 30 [0014] An embodiment comprises a protein biomatrix in both sheet or sleeve and particle form that incorporates both hydroxyapatite (HAp) and collagen for use in the treatment of orthopedic injuries. However, it is noted that other bio- compatible proteins and reagents may also be utilized in the present invention. [0015] Another embodiment includes a method of implanting and securing an implant system combining both biomatrix sheet and particle form for the treatment of segmental defects, nonunion, and delayed union fractures. 35 [0016] Still another embodiment includes a method of making an implant system including a biomaterial in both sheet or sleeve and particle form for the treatment of segmental defects, nonunion and delayed union fractures. [0017] The current invention is intended to provide new materials, devices and treatment methods to address non union fractures or those characterized by segmented defects or other bone fractures that heal slowly or not well due to disease, trauma or age. However, the present invention may also be utilized to repair fractures or damage to other parts 40 of the body such as tendons and nerves (e.g. spinal cord and optical nerve). The present invention improves current therapies by using both a containment sleeve to isolate bone, tendon or nerve healing from soft tissue and by adding therapeutic bone, tendon or nerve mending particles, such as collagen-HAp particles to act as healing scaffolds, both of which provide local drug delivery and local cell integration to the site of healing. For example the administration of sleeves and/or particles including bone mending biochemicals (e.g., hydroxyapatite), growth factors (e.g., bone mor- 45 phogenic protein) or other therapeutic agents (e.g., antibacterial, analgesics, anesthetic) can assist in reducing the time of recovery and enhance the proper mending of the injured part of the body. Finally, the containment and fixation device can facilitate and organize wound healing with and without the addition of growth factors (e.g. angiogenic growth factors) and/or other drugs. For example, the sleeve and particles of the present invention provides organization for the sur- rounding bone and tissue to heal along a defined scaffolding rather than healing over a tissue and/or bone defect. The 50 containment sleeve being in close contact with the periosteal bone/tissue further promotes the vascularization during healing by providing a connection across the defect.

BRIEF DESCRIPTION OF THE DRAWINGS

55 [0018]

Figure 1 depicts a histology slide from a sciatic nerve study including one embodiment of the biomatrix material of the present invention;

3 EP 1 528 894 B1

Figure 2 depicts a histological image including an implant of one embodiment of the biomatrix material of the present invention; Figure 3 depicts images of cell growth on one embodiment of the biomatrix material of the present invention; Figure 4 depicts one embodiment of the containment sleeve of the present invention comprising a biomatrix material 5 that is fastened with sutures; Figure 5 depicts the elasticity of one embodiment of the containment sleeve of the present invention comprising a biomatrix material; Figure 6 depicts particles of the present invention which include the biomatrix material; Figure 7 depicts an image of a bone non-union defect model; 10 Figure 8 depicts a process for administering the containment and fixation system of the present invention to a bone non-union defect.

DETAILED DESCRIPTION OF THE INVENTION

15 [0019] The fixation system of the present invention generally includes a containment and fixation sleeve, optionally in combination with biomatrix particles. In many embodiments of the present invention, the sleeve and particles are com- monly made of a biomatrix material. The biomatrix material is comprised of one or more biocompatible proteins and one or more biocompatible solvents. The biomatrix material utilized in the sleeve and/or particles may also include one or more therapeutic biochemicals such as a bone mending biochemical, such as hydroxyapatite or an angiogenic growth 20 factor such as BMP. [0020] The biomatrix material is designed to retain the protein’s natural activity combined with the ability to form it into various shapes with structural integrity. The biomatrix material is further designed to mimic the architectural framework of the body to support natural tissue growth. The biomatrix material is biointegratable thereby allowing the integration and remodeling of the biomatrix material by the host tissue. In addition to the ability to act as a structural scaffold, the 25 ability to customize the material properties to the application, to mold the material into any defined shape, and to incor- porate other substances such as pharmacologically active agents (drugs), particles, or other structural materials, into the base matrix also make the biomatrix material unique. [0021] As previously mentioned the biomatrix materials are generally comprised of one or more biocompatible proteins, one or more biocompatible solvents and optionally one or more pharmacologically active agents. It is noted that additional 30 additive materials such as polymers and/or therapeutic entities may be included in the material to provide various beneficial features such as strength, elasticity, structure, enhanced biocompatibility and/or any other desirable charac- teristics. In various embodiments of the present invention, the sleeves and/or particles prepared utilizing the biomatrix materials possess a relatively homogeneous distribution of the components, including a homogenous distribution of any bone mending biochemicals, angiogenic growth factors or other pharmacologically active agents. 35 [0022] The biomatrix materials nominally comprise one or more biocompatible synthetic proteins, genetically-engi- neered proteins, natural proteins or any combination thereof. In many embodiments of the present invention, the biomatrix materials comprise a water-absorbing, biocompatible protein. The utilization of a water-absorbing biocompatible protein provides the advantage that, not only will the biocompatible protein particles be bioresorbable, but may remodel to mimic and support the tissue it contacts. That is, the metabolites of any degradation and/or resorption of the water-absorbing 40 biocompatible protein may be reused by the patient’s body rather than excreted. [0023] Additionally, the proteins of the present invention are generally purified and in a free-form state. Normally, free- form proteins are comprised of protein molecules that are not substantially crosslinked to other protein molecules, unlike tissues or gelatins. Normally, tissue or gelatin is already in a crosslinked matrix form and is thereby limited in forming new intermolecular or intramolecular bonds. Therefore, the free-form protein molecules when added to solvent have the 45 capacity to freely associate or intermingle with each other and other molecules or particles, such as solvents or phar- macologically active agents. [0024] As previously suggested, the biocompatible protein utilized may either be naturally occurring, synthetic or genetically engineered. Naturally occurring protein that may be utilized in the containment and fixation system of the present invention include, but are not limited to elastin, collagen, albumin, ovalbumin, keratin, fibronectin, silk, silk fibro in, 50 actin, myosin, fibrinogen, thrombin, aprotinin, antithrombin III and any other biocompatible natural protein. Examples of proteins that are commercially available and may be utilized in some embodiments of the present invention include Type I soluble or insoluable collagen, insoluable or soluable elastin, soluable albumen manufactured by Kensey Nash Cor- poration, 55 East Uwchlan Avenue, Exton, PA 19341, Sigma-Aldrich Corporation, St. Louis, MO, USA or Elastin Products Company, Inc., P.O. Box 568, Owensville, Missouri, USA 65066. It is noted that combinations of natural proteins may 55 be utilized to optimize desirable characteristics of the resulting biomatrix materials, such as strength, degradability, resorption, etc. Inasmuch as heterogeneity in molecular weight, sequence and stereochemistry can influence the function of a protein in a biomatrix material, in some embodiments of the present invention synthetic or genetically engineered proteins are preferred in that a higher degree of control can be exercised over these parameters.

4 EP 1 528 894 B1

[0025] As previously suggested the proteins of the present invention are generally purified proteins. The purity of each natural protein component mixed in the coatable composition phase (the coatable composition will be described further below) during production of particles include 20% or less other proteins or impurities, preferably 10% or less other proteins or impurities, more preferably 3% or less other proteins or impurities and if available ideally 1% or less other 5 proteins or impuritites. [0026] Synthetic proteins are generally prepared by chemical synthesis utilizing techniques known in the art. Also, individual proteins may be chemically combined with one or more other proteins of the same or different type to produce a dimer, trimer or other multimer. A simple advantage of having a larger protein molecule is that it will make intercon- nections with other protein molecules to create a stronger biomatrix material that is less susceptible to dissolving in 10 aqueous solutions and provides additional protein structural and biochemical characteristics. [0027] Additional, protein molecules can also be chemically combined to any other chemical so that the chemical does not release from the biomatrix materials. In this way, the chemical entity can provide surface modifications to the biomatrix materials or structural contributions to the material to produce specific characteristics. The surface modifications can enhance and/or facilitate cell attachment depending on the chemical substance or the cell type. The structural modifi- 15 cations can be used to facilitate or impede dissolution, enzymatic degradation or dissolution of the biomatrix material. [0028] Synthetic biocompatible proteins may be cross-linked, linked, bonded, chemically and/or physically linked to pharmacological active agents, enzymatically, chemically or thermally cleaved and utilized alone or in combination with other biocompatible proteins or partial proteins e.g. peptides, to form the biomatrix materials. Examples of such synthetic biocompatible proteins include, but are not limited to heparin-protein, heparin-polymer, chondroitin-protein, chondroitin- 20 polymer, heparin-cellulose, heparin-alginate, heparin-polylactide, GAGs-collagen, heparin-collagen, collagen-elastin- heparin, collagen-albumin, collagen-albumin-elastin-heparin, collagen-hyaluronic acid, collagen-albumin-heparin, col- lagen-chondroitin-heparin, collagen-chondroitin and the like. [0029] A specific example of a particularly preferred genetically engineered protein for use in the biocompatible protein particles of the present invention is human collagen produced by FibroGen, Inc., 225 Gateway Blvd., South San Francisco, 25 CA 94080. Other specific examples of particularly preferred genetically engineered proteins for use in the biomatrix materials of the present invention are commercially available under the nomenclature "ELP", "SLP", "CLP", "SLPL", "SLPF" and "SELP" from Protein Polymer Technologies, Inc. San Diego, CA. ELP’s, SLP’s, CLP’s, SLPL’s, SLPF’s and SELP’s are families of genetically engineered protein polymers consisting of silklike blocks, elastinlike blocks, collagenlike blocks, lamininlike blocks, fibronectinlike blocks and the combination of silklike and elastinlike blocks, respectively. The 30 ELP’s, SLP’s, CLP’s, SLPL’s, SLPF’s and SELP’s are produced in various block lengths and compositional ratios. Generally, blocks include groups of repeating amino acids making up a peptide sequence that occurs in a protein. Genetically engineered proteins are qualitatively distinguished from sequential polypeptides found in nature in that the length of their block repeats can be greater (up to several hundred amino acids versus less than ten for sequential polypeptides) and the sequence of their block repeats can be almost infinitely complex. Table A depicts examples of 35 genetically engineered blocks. Table A and a further description of genetically engineered blocks may be found in Franco A. Ferrari and Joseph Cappello, Biosynthesis of Protein Polymers, in: Protein-Based Materials, (eds., Kevin McGrath and David Kaplan), Chapter 2, pp. 37-60, Birkhauser, Boston (1997).

Table A. Protein polymer sequences 40 Polymer Name Monomer Amino Acid Sequence

SLP 3 [(GAGAGS)9 GAAGY)] SLP 4 (GAGAGS)n SLP F [(GAGAGS)9 GAA VTGRGDSPAS AAGY]n 45 SLP L3.0 [(GAGAGS)9 GAA PGASIKVAVSAGPS AGY]n SLP L3.1 [(GAGAGS)9 GAA PGASIKVAVSGPS AGY]n SLP F9 [(GAGAGS)9 RYVVLPRPVCFEK AAGY]n ELP I [(VPGVG)4]n SELP 0 [(GVGVP) (GAGAGS) ] 50 8 2 n SELP 1 [GAA (VPGVG)4 VAAGY (GAGAGS)9]n SELP 2 [(GAGAGS)6 GAAGY (GAGAGS)5 (GVGVP)8]n SELP 3 [(GVGVP)8 (GAGAGS)8]n SELP 4 [(GVGVP)12 (GAGAGS)8]n 55 SELP 5 [(GVGVP)16 (GAGAGS)8]n SELP 6 [(GVGVP)32 (GAGAGS)8]n SELP 7 [(GVGVP)8 (GAGAGS)6]n

5 EP 1 528 894 B1

(continued)

Polymer Name Monomer Amino Acid Sequence

SELP 8 [(GVGVP)8 (GAGAGS)4]n 5 KLP 1.2 [(AKLKLAEAKLELAE)4]n CLP 1 [GAP(GPP)4]n CLP 2 {[GAP(GPP)4]2 GPAGPVGSP}n CLP-CB {[GAP(GPP)4]2 (GLPGPKGDRGDAGPKGADGSPGPA) GPAGPVGSP}n

10 CLP 3 (GAPGAPGSQGAPGLQ)n Repetitive amino acid sequences of selected protein polymers. SLP = silk like protein; SLPF = SLP containing the RGD sequence from fibronectin; SLPL 3/0 and SLPL 3/1 = SLP containing two difference sequences from laminin protein; ELP = elastin like protein; SELP = silk elastin like protein; CLP = collagen like protein; CLP-CB = CLP containing a cell binding domain from human collagen; KLP = keratin like protein 15

The nature of the elastinlike blocks, and their length and position within the monomers influences the water solubility of the SELP polymers. For example, decreasing the length and/or content of the silklike block domains, while maintaining the length of the elastinlike block domains, increases the water solubility of the polymers. For a more detailed discussion of the production of SLP’s, ELP’s, CLP’s, SLPF’s and SELP’s as well as their properties and characteristics see, for 20 example, in J. Cappello et al., Biotechnol. Prog., 6, 198 (1990), the full disclosure of which is incorporated by reference herein. One preferred SELP, SELP7, has an elastin:silk ratio of 1.33, and has 45% silklike protein material and is believed to have weight average molecular weight of 80,338. [0030] The biomatrix material utilized in various embodiments of the present invention also include one or more biocompatible solvents. Any biocompatible solvent may be utilized in the method and corresponding biomatrix material 25 of the present invention. By using a biocompatible solvent, the risk of adverse tissue reactions to residual solvent remaining in the device after manufacture is minimized. Additionally, the use of a biocompatible solvent reduces the potential structural and/or pharmacological degradation of the pharmacologically active agent that some such pharma- cologically active agents undergo when exposed to organic solvents. Suitable biocompatible solvents for use in the method of the present invention include, but are not limited to, water; dimethyl sulfoxide (DMSO); biocompatible alcohols, 30 such as glycerol, methanol and ethanol; various acids, such as formic acid; oils, such as olive oil, peanut oil and the like; ethylene glycol, glycols; and combinations of these and the like. Preferably, the biocompatible solvent comprises water. The amount of biocompatible solvent utilized in the coatable composition will preferably be that amount sufficient to result in the composition being fluid and flowable enough to be coatable. Generally, the amount of biocompatible solvent suitable for use in the method of the present invention will range from about 50% to about 1000%, preferably 35 from about 100% to about 300% by weight, based upon the weight and/or amount of the protein utilized. [0031] In addition to the biocompatible protein(s) and the biocompatible solvent(s), the biomatrix material that may be utilized in various embodiments of the present invention may include one or more pharmacologically active agents. As used herein, "pharmacologically active agent" generally refers to a pharmacologically active agent having a direct or indirect beneficial therapeutic effect upon introduction into a host. Pharmacologically active agents further includes 40 neutraceuticals. The phrase "pharmacologically active agent" is also meant to indicate prodrug forms thereof. A "prodrug form" of a pharmacologically active agent means a structurally related compound or derivative of the pharmacologically active agent which, when administered to a host is converted into the desired pharmacologically active agent. A prodrug form may have little or none of the desired pharmacological activity exhibited by the pharmacologically active agent to which it is converted. Representative examples of pharmacologically active agents that may be suitable for use in the 45 protein matrix device of the present invention include, but are not limited to, (grouped by therapeutic class):

Antidiarrhoeals such as diphenoxylate, loperamide and hyoscyamine; Antihypertensives such as hydralazine, minoxidil, captopril, enalapril, clonidine, prazosin, debrisoquine, diazoxide, guanethidine, methyldopa, reserpine, trimethaphan; 50 Calcium channel blockers such as diltiazem, felodipine, amlodipine, nitrendipine, nifedipine and verapamil; Antiarrhyrthmics such as amiodarone, flecainide, disopyramide, procainamide, mexiletene and quinidine, Antiangina agents such as glyceryl trinitrate, erythrityl tetranitrate, pentaerythritol tetranitrate, mannitol hexanitrate, perhexilene, isosorbide dinitrate and nicorandil; Beta-adrenergic blocking agents such as alprenolol, atenolol, bupranolol, carteolol, labetalol, metoprolol, nadolol, 55 nadoxolol, oxprenolol, pindolol, propranolol, sotalol, timolol and timolol maleate; Cardiotonic glycosides such as digoxin and other cardiac glycosides and theophylline derivatives; Adrenergic stimulants such as adrenaline, ephedrine, fenoterol, isoprenaline, orciprenaline, rimeterol, salbutamol,

6 EP 1 528 894 B1

salmeterol, terbutaline, dobutamine, phenylephrine, phenylpropanolamine, pseudoephedrine and dopamine; Vasodilators such as cyclandelate, isoxsuprine, papaverine, dipyrimadole, isosorbide dinitrate, phentolamine, nico- tinyl alcohol, co-dergocrine, nicotinic acid, glycerl trinitrate, pentaerythritol tetranitrate and xanthinol; Antiproliferative agents such as paclitaxel, actinomycin D, sirolimus, tacrolimus, everolimus and dexamethasone; 5 Antimigraine preparations such as ergotanmine, dihydroergotamine, methysergide, pizotifen and sumatriptan; Anticoagulants and thrombolytic agents such as warfarin, dicoumarol, low molecular weight heparins such as enox- aparin, streptokinase and its active derivatives; Hemostatic agents such as aprotinin, tranexamic acid and protamine; Analgesics and antipyretics including the opioid analgesics such as buprenorphine, dextromoramide, dextropropox- 10 yphene, fentanyl, alfentanil, sufentanil, hydromorphone, methadone, morphine, oxycodone, papaveretum, penta- zocine, pethidine, phenopefidine, codeine dihydrocodeine; acetylsalicylic acid (aspirin), paracetamol, and phena- zone; Immunosuppressants, antiproliferatives and cytostatic agents such as rapomycin (sirolimus) and its analogs (everolimus and tacrolimus); 15 Neurotoxins such as capsaicin, botulinum toxin (botox); Hypnotics and sedatives such as the barbiturates amylobarbitone, butobarbitone and pentobarbitone and other hypnotics and sedatives such as chloral hydrate, chlormethiazole, hydroxyzine and meprobamate; Antianxiety agents such as the benzodiazepines alprazolam, bromazepam, chlordiazepoxide, clobazam, chloraze- pate, diazepam, flunitrazepam, flurazepam, lorazepam, nitrazepam, oxazepam, temazepam and triazolam; 20 Neuroleptic and antipsychotic drugs such as the phenothiazines, chlorpromazine, fluphenazine, pericyazine, per- phenazine, promazine, thiopropazate, thioridazine, trifluoperazine; and butyrophenone, droperidol and haloperidol; and other antipsychotic drugs such as pimozide, thiothixene and lithium; Antidepressants such as the tricyclic antidepressants amitryptyline, clomipramine, desipramine, dothiepin, doxepin, imipramine, nortriptyline, opipramol, protriptyline and trimipramine and the tetracyclic antidepressants such as mi- 25 anserin and the monoamine oxidase inhibitors such as isocarboxazid, phenelizine, tranylcypromine and mo- clobemide and selective serotonin re-uptake inhibitors such as fluoxetine, paroxetine, citalopram, fluvoxamine and sertraline; CNS stimulants such as caffeine and 3-(2-aminobutyl) indole; Anti-alzheimer’s agents such as tacrine; 30 Anti-Parkinson’s agents such as amantadine, benserazide, carbidopa, levodopa, benztropine, biperiden, benzhexol, procyclidine and dopamine-2 agonists such as S (-)-2 -(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0923), Anticonvulsants such as phenytoin, valproic acid, primidone, phenobarbitone, methylphenobarbitone and car- bamazepine, ethosuximide, methsuximide, phensuximide, sulthiame and clonazepam, Antiemetics and antinauseants such as the phenothiazines prochloperazine, thiethylperazine and 5HT-3 receptor 35 antagonists such as ondansetron and granisetron, as well as dimenhydrinate, diphenhydramine, metoclopramide, domperidone, hyoscine, hyoscine hydrobromide, hyoscine hydrochloride, clebopride and brompride; Non-steroidal anti-inflammatory agents including their racemic mixtures or individual enantiomers where applicable, preferably which can be formulated in combination with dermal and/or mucosal penetration enhancers, such as ibuprofen, flurbiprofen, ketoprofen, aclofenac, diclofenac, aloxiprin, aproxen, aspirin, diflunisal, fenoprofen, in- 40 domethacin, mefenamic acid, naproxen, phenylbutazone, piroxicam, salicylamide, salicylic acid, sulindac, desox- ysulindac, tenoxicam, tramadol, ketoralac, flufenisal, salsalate, triethanolamine salicylate, aminopyrine, antipyrine, oxyphenbutazone, apazone, cintazone, flufenamic acid, clonixerl, clonixin, meclofenamic acid, flunixin, coichicine, demecolcine, allopurinol, oxypurinol, benzydamine hydrochloride, dimefadane, indoxole, intrazole, mimbane hydro- chloride, paranylene hydrochloride, tetrydamine, benzindopyrine hydrochloride, fluprofen, ibufenac, naproxol, fen- 45 bufen, cinchophen, diflumidone sodium, fenamole, flutiazin, metazamide, letimide hydrochloride, nexeridine hydro- chloride, octazamide, molinazole, neocinchophen, nimazole, proxazole citrate, tesicam, tesimide, tolmetin, and triflumidate; Antirheumatoid agents such as penicillamine, aurothioglucose, sodium aurothiomalate, methotrexate and auranofin; Muscle relaxants such as baclofen, diazepam, cyclobenzaprine hydrochloride, dantrolene, methocarbamol, orphen- 50 adrine and quinine; Agents used in gout and hyperuricaemia such as allopurinol, colchicine, probenecid and sulphinpyrazone; Oestrogens such as oestradiol, oestriol, oestrone, ethinyloestradiol, mestranol, stilboestrol, dienoestrol, epioestriol, estropipate and zeranol; Progesterone and other progestagens such as allyloestrenol, dydrgesterone, lynoestrenol, norgestrel, norethyndrel, 55 norethisterone, norethisterone acetate, gestodene, levonorgestrel, medroxyprogesterone and megestrol; Antiandrogens such as cyproterone acetate and danazol; Antioestrogens such as tamoxifen and epitiostanol and the aromatase inhibitors, exemestane and 4-hydroxy-an- drostenedione and its derivatives;

7 EP 1 528 894 B1

Androgens and anabolic agents such as testosterone, methyltestosterone, clostebol acetate, drostanolone, furazabol, nandrolone oxandrolone, stanozolol, trenbolone acetate, dihydro-testosterone, 17-(α-methyl-19-nories- tosterone and fluoxymesterone; 5-alpha reductase inhibitors such as finasteride, turosteride, LY- 191704 and MK-306; 5 Corticosteroids such as betamethasone, betamethasone valerate, cortisone, dexamethasone, dexamethasone 21- phosphate, fludrocortisone, flumethasone, fluocinonide, fluocinonide desoude, fluocinolone, fluocinolone acetonide, fluocortolone, halcinonide, halopredone, hydrocortisone, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, hydrocortisone 21-acetate, methylprednisolone, prednisolone, prednisolone 21 -phosphate, prednisone, triamci- nolone, triamcinolone acetonide; 10 Glycosylated proteins, proteoglycans, glycosaminoglycans such as chondroitin sulfate; chitin, acetyl-glucosamine, hyaluronic acid; Complex carbohydrates such as glucans; Further examples of steroidal anti-inflammatory agents such as cortodoxone, fludroracetonide, fludrocortisone, difluorsone diacetate, flurandrenolone acetonide, medrysone, amcinafel, amcinafide, betamethasone and its other 15 esters, chloroprednisone, clorcortelone, descinolone, desonide, dichlorisone, difluprednate, flucloronide, flumetha- sone, flunisolide, flucortolone, fluoromethalone, fluperolone, fluprednisolone, meprednisone, methylmeprednisolo- ne, paramethasone, cortisone acetate, hydrocortisone cyclopentylpropionate, cortodoxone, flucetonide, fludrocor- tisone acetate, aincinafal, amcinafide, betamethasone, betamethasone benzoate, chloroprednisone acetate, cloco- rtolone acetate, descinolone acetonide, desoximetasone, dichlorisone acetate, difluprednate, flucloronide, flumeth- 20 asone pivalate, flunisolide acetate, fluperolone acetate, fluprednisolone valerate, paramethasone acetate, pred- nisolamate, prednival, triamcinolone hexacetonide, cortivazol, formocortal and nivazol; Pituitary hormones and their active derivatives or analogs such as corticotrophin, thyrotropin, follicle stimulating hormone (FSH), luteinising hormone (LH) and gonadotrophin releasing hormone (GnRH); Hypoglycemic agents such as insulin, chlorpropamide, glibenclamide, gliclazide, glipizide, tolazamide, tolbutamide 25 and metformin; Thyroid hormones such as calcitonin, thyroxine and liothyronine and antithyroid agents such as carbimazole and propylthiouracil; Other miscellaneous hormone agents such as octreotide; Pituitary inhibitors such as bromocriptine; 30 Ovulation inducers such as clomiphene; Diuretics such as the thiazides, related diuretics and loop diuretics, bendrofluazide, chlorothiazide, chlorthalidone, dopamine, cyclopenthiazide, hydrochlorothiazide, indapamide, mefruside, methycholthiazide, metolazone, quinet- hazone, bumetanide, ethacrynic acid and frusemide and potasium sparing diuretics, spironolactone, amiloride and triamterene; 35 Antidiuretics such as desmopressin, lypressin and vasopressin including their active derivatives or analogs; Obstetric drugs including agents acting on the uterus such as ergometrine, oxytocin and gemeprost; Prostaglandins such as alprostadil (PGE1), prostacyclin (PGI2), dinoprost (prostaglandin F2-alpha) and misoprostol; Antimicrobials including the cephalosporins such as cephalexin, cefoxytin and cephalothin; Penicillins such as amoxycillin, amoxycillin with clavulanic acid, ampicillin, bacampicillin, benzathine penicillin, ben- 40 zylpenicillin, carbenicillin, cloxacillin, methicillin, phenethicillin, phenoxymethylpenicillin, flucloxacillin, meziocillin, piperacillin, ticarcillin and azlocillin; Tetracyclines such as minocycline, chlortetracycline, tetracycline, demeclocycline, doxycycline, methacycline and oxytetracycline and other tetracycline-type antibiotics; Amnioglycoides such as amikacin, gentamicin, kanamycin, neomycin, netilmicin and tobramycin; 45 Antifungals such as amorolfine, isoconazole, clotrimazole, econazole, miconazole, nystatin, terbinafine, bifonazole, amphotericin, griseofulvin, ketoconazole, fluconazole and flucytosine, salicylic acid, fezatione, ticlatone, tolnaftate, triacetin, zinc, pyrithione and sodium pyrithione; Quinolones such as nalidixic acid, cinoxacin, ciprofloxacin, enoxacin and norfloxacin; Sulphonamides such as phthalysulphthiazole, sulfadoxine, sulphadiazine, sulphamethizole and sulphamethoxazole; 50 Sulphones such as dapsone; Other miscellaneous antibiotics such as chloramphenicol, clindamycin, erythromycin, erythromycin ethyl carbonate, erythromycin estolate, erythromycin glucepate, erythromycin ethylsuccinate, erythromycin lactobionate, roxithromy- cin, lincomycin, natamycin, nitrofurantoin, spectinomycin, vancomycin, aztreonarn, colistin IV, metronidazole, tini- dazole, fusidic acid, trimethoprim, and 2-thiopyridine N-oxide; halogen compounds, particularly iodine and iodine 55 compounds such as iodine-PVP complex and diiodohydroxyquin, hexachlorophene; chlorhexidine; chloroamine compounds; and benzoylperoxide; Antituberculosis drugs such as ethambutol, isoniazid, pyrazinamide, rifampicin and clofazimine; Antimalarials such as primaquine, pyrimethamine, chloroquine, hydroxychloroquine, quinine, mefloquine and halo-

8 EP 1 528 894 B1

fantrine; Antiviralagents such as acyclovir and acyclovir prodrugs,famcyclovir, zidovudine, didanosine, stavudine, lamivudine, zalcitabine, saquinavir, indinavir, ritonavir, n-docosanol, tromantadine and idoxuridine; Anthelmintics such as mebendazole, thiabendazole, niclosamide, praziquantel, pyrantel embonate and diethylcar- 5 bamazine; Cytotoxic agents such as plicamycin, cyclophosphamide, dacarbazine, fluorouracil and its prodrugs (described, for example, in International Journal of Pharmaceutics, 111, 223-233 (1994)), methotrexate, procarbazine, 6-mercap- topurine and mucophenolic acid; Anorectic and weight reducing agents including dexfenflurarnine, fenfluramine, diethylpropion, mazindol and phen- 10 termine; Agents used in hypercalcaemia such as calcitriol, dihydrotachysterol and their active derivatives or analogs; Antitussives such as ethylmorphine, dextromethorphan and pholcodine; Expectorants such as carbolcysteine, bromhexine, emetine, quanifesin, ipecacuanha and saponins; Decongestants such as phenylephrine, phenylpropanolamine and pseudoephedrine; 15 Bronchospasm relaxants such as ephedrine, fenoterol, orciprenaline, rimiterol, salbutamol, sodium cromoglycate, cromoglycic acid and its prodrugs (described, for example, in International Journal of Pharmaceutics 7, 63-75 (1980 )), terbutaline, ipratropium bromide, salmeterol and theophylline and theophylline derivatives; Antihistamines such as meclozine, cyclizine, chlorcyclizine, hydroxyzine, brompheniramine, chlorpheniramine, clem- astine, cyproheptadine, dexchlorpheniramine, diphenhydramine, diphenylamine, doxylamine, mebhydrolin, phe- 20 niramine, tripolidine, azatadine, diphenylpyraline, methdilazine, terfenadine, astemizole, loratidine and cetirizine; Local anaesthetics such as benzocaine bupivacaine, amethocaine, lignocaine, lidocaine, cinchocaine, dibucaine, mepivacaine, prilocaine, etidocaine, veratridine (specific c-fiber blocker) and procaine; Stratum corneum lipids, such as ceramides, cholesterol and free fatty acids, for improved skin barrier repair [Man, et al. J. Invent. Dermatol., 106(5), 1096, (1996)]; 25 Neuromuscular blocking agents such as suxamethonium, alcuronium, pancuronium, atracurium, gallamine, tubocurarine and vecuronium; Smoking cessation agents such as nicotine, bupropion and ibogaine; Insecticides and other pesticides which are suitable for local application; Dermatological agents, such as vitamins A, C, B1, B2, B6, B12, B12 α., and E, vitamin E acetate and vitamin E sorbate; 30 Allergens for desensitisation such as house, dust or mite allergens; Nutritional agents and neutraceuticals, such as vitamins, essential amino acids and fats; Macromolecular pharmacologically active agents such as proteins, enzymes, peptides, polysaccharides (such as cellulose, amylose, dextran, chitin), nucleic acids, cells, tissues, and the like; Bone mending biochemicals such as calcium carbonate, calcium phosphate, hydroxyapetite or bone morphogenic 35 protein (BMP); Angiogenic growth factors such as Vascular Endothelial Growth Factor (VEGF) and epidermal growth factor (EFG), cytokines interleukins, fibroblasts and cytotaxic chemicals; and Keratolytics such as the alpha-hydroxy acids, glycolic acid and salicylic acid; and DNA, RNA or other oligonucleotides.

40 [0032] Additionally, the biomatrix materials of the present invention are particularly advantageous for the encapsulation, incorporation and/or scaffolding of macromolecular pharmacologically active agents such as proteins, enzymes, peptides, polysaccharides, nucleic acids, cells, tissues, and the like. Immobilization of macromolecular pharmacologically active agents into or onto a particle can be difficult due to the ease with which some of these macromolecular agents denature when exposed to organic solvents, some constituents present in bodily fluids or to temperatures appreciably higher than 45 room temperature. However, since the method of the present invention utilizes biocompatible solvents such as water, DMSO or ethanol the risk of the denaturation of these types of materials is reduced. Furthermore, due to the size of these macromolecular pharmacologically active agents, these agents may be encapsulated within the biocompatible protein sleeves and particles and thereby are protected from constituents of bodily fluids that would otherwise denature them. Thus, the biomatrix materials of the present invention allow these macromolecular agents to exert their therapeutic 50 effects, while yet protecting them from denaturation or other structural degradation. [0033] Examples of cells which can be utilized as the pharmacologically active agent in the biomatrix material and/or biocompatible protein particles of the present invention include primary cultures as well as established cell lines, including transformed cells. Examples of these include, but are not limited to pancreatic islet cells, human foreskin fibroblasts, Chinese hamster ovary cells, beta cell insulomas, lymphoblastic leukemia cells, mouse 3T3 fibroblasts, dopamine se- 55 creting ventral mesencephalon cells, neuroblastold cells, adrenal medulla cells, endothelial cells, T-cells combinations of these, and the like. As can be seen from this partial list, cells of all types, including dermal, neural, blood, organ, stem , muscle, glandular, reproductive and immune system cells, as well as cells of all species of origin, can be encapsulated and/or delivered successfully by this method.

9 EP 1 528 894 B1

[0034] Examples ofproteins which can beincorporated into the biomatrixmaterial and/orbiocompatible protein particles of the present invention include, but are not limited to, hemoglobin, vasporessin, oxytocin, adrenocorticocotrophic hor- mone, epidermal growth factor, prolactin, luliberin or luteinising hormone releasing factor, human growth factor, and the like; enzymes such as adenosine deaminase, superoxide dismutase, xanthine oxidase, and the like; enzyme systems; 5 blood clotting factors; clot inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator; antigens for immunization; hormones; polysaccharides such as heparin and rituximab; oligonucleotides; bacteria and other microbial microorganisms including viruses; monoclonal antibodies, such as herceptin; vitamins; cofactors; growth factors; retroviruses for gene therapy, combinations of these and the like. [0035] An efficacious amount of the aforementioned pharmacologically active agent(s) can easily be determined by 10 those of ordinary skill in the art taking into consideration such parameters as the particular pharmacologically active agent chosen, the size and weight of the patient, the desired therapeutic effect, the pharmacokinetics of the chosen pharmacologically active agent, and the like, as well as by reference to well known resources such as Physicians’ Desk Reference®: PDR--52 ed (1998)--Medical Economics 1974. In consideration of these parameters, it has been found that a wide range exists in the amount of the pharmacologically active agent(s) capable of being incorporated into and 15 subsequently released from or alternatively allowed to exert the agent’s therapeutic effects from within, the biomatrix material and/or biocompatible protein particles. More specifically, the amount of pharmacologically active agent that may be incorporated into and then either released from or active from within the biomatrix material and/or biocompatible protein particles may range from about 0.001% to about 200%, more preferably, from about 0.05% to about 100%, most preferably from about 0. 1% to 70%, based on the weight of the biomatrix material and/or biocompatible protein particles. 20 It is important to note that the pharmacologically active agents are generally homogenously distributed throughout the biomatrix material and/or biocompatible protein particles thereby allowing for a controlled release of these agents. [0036] Finally, one or more additive materials may be added to the biomatrix material to manipulate the material properties and thereby add additional structure or modify the release of pharmacologically active agents. That is, while a biomatrix material that includes a relatively fast-degrading protein material without a particular additive material will 25 readily degrade thereby releasing drug relatively quickly upon insertion or implantation, a biomatrix material that includes a particular polymeric material, such as polyanhydride, will degrade slowly, as well as release the pharmacologically active agent(s) over a longer period of time. Examples of biodegradable and/or biocompatible additive materials suitable for use in the biomatrix materials utilized in the sleeves and/or particles of the present invention include, but are not limited to polyurethanes, vinyl homopolymers and copolymers, acrylate homopolymers and copolymers, polyethers, 30 cellulosics, epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, poly(ethylene terephthalate), polyacetal, po- ly(lactic acid), poly(ethylene oxide)/poly(butylene terephthalate) copolymer, polycarbonate, poly(tetrafluoroethylene) (PTFE), polycaprolactone, polyethylene oxide, polyethylene glycol, poly(vinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol (PVA), 2-hydroxyethyl meth- acrylate (HEMA), polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, 35 polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV), poly(ethylene oxide) (PEO), poly ortho esters, poly (amino acids), polycynoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluor- opolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, copolymers of these, and the like. Other materials that may be incorporated into the biomatrix material to provide enhanced features include, but are not limited to, ceramics, bioceramics, glasses bioglasses, glass-ceramics, resin cement, resin fill; more 40 specifically, glass ionomer, hydroxyapatite, calcium sulfate, Al 2O3, tricalcium phosphate, calcium phosphate salts, sug- ars, starches, carbohydrates, salts, polysaccharides, alginate and carbon. Additional other materials that may be incor- porated into the biomatrix materials included alloys such as, cobalt-based, galvanic- based, stainless steel- based, titanium-based, zirconium oxide, zirconia, aluminum- based, vanadium- based, molybdenum-based, nickel- based, iron- based, or zinc- based (zinc phosphate, zinc polycarboxylate). 45 [0037] One method of producing the biomatrix materials is by providing one or more selected biocompatible proteins, adding other materials (pharmacologically active agents, additives, etc.) and solvents (water) to form a coatable com- position. Once prepared, the coatable composition may be coated onto any suitable surface from which it may be released after drying by any suitable method. Examples of suitable coating techniques include spin coating, gravure coating, flow coating, spray coating, coating with a brush or roller, screen printing, knife coating, curtain coating, slide curtain coating, 50 extrusion, squeegee coating, and the like. The coated film (preferably having a substantially planar body having opposed major surfaces) is desirably thin enough so as to be capable of drying within a reasonable amount of time and also thin enough so that the film can be formed into a cohesive body comprising a substantially homogeneous dispersion of the components of the coatable composition. For example, a thinner film will tend to form a more homogeneous cohesive body when the film is formed into the shape of a cylinder. A typical coated film of the coatable composition have a 55 thickness in the range of from about 0.01 millimeters to about 5 millimeters, more preferably from about 0.05 mi llimeters to about 2 millimeters. [0038] Initially, when the film is first coated, it is likely to be non-cohesive, fluidly-flowable, and/or non self-supporting. Thus, the coated film is preferably dried sufficiently so that it becomes cohesive, i.e., the film preferably sticks to itself

10 EP 1 528 894 B1

rather than other materials. The film may simply be allowed to dry at room temperature, or alternatively, may be dried under vacuum, conditions of mild heating, i.e., heating to a temperature of from about 25°C to about 150°C, or conditions of mild cooling, i.e. cooling to a temperature of from about 0°C to about 20°C. When utilizing heat to dry the film, care should be taken to avoid denaturation or structural degradation of the pharmacologically active agent incorporated therein. 5 [0039] The specific solvent content at which the film becomes cohesive unto itself will depend on the individual com- ponents incorporated into the coatable composition. Generally, films that have too high of a solvent content will not be cohesive. Films that have too low of a solvent content will tend to crack, shatter, or otherwise break apart upon efforts to form them into a cohesive body. With these considerations in mind, the solvent content of a partially dried film will preferably be from about 10% to about 80%, more preferably from about 15% to about 65% and most preferably from 10 about 20% to about 50%. [0040] Once the film is capable of forming a cohesive body, such a cohesive body may be formed by any of a number of methods. For example, the film may be rolled, folded, accordion-pleated, crumpled, or otherwise shaped such that the resulting cohesive body has a surface area that is less than that of the coated film. For example the film can be shaped into a cylinder, a cube, a sphere or the like. Preferably, the cohesive body is formed by rolling the coated film 15 to form a cylinder. [0041] Once so formed, the cohesive body may be optionally compressed to form a biomatrix material. The biomatrix material may be formed into any number of shapes and sizes. For example to prepare the fixation sleeves of the present invention the biomatrix material may be formed into a sheet of the appropriate size to extend around and cover the injured part of the body, such as a fractured bone. Alternatively, the biomatrix material may be formed into a cylinder for 20 subsequent pulverization into particles (an explanation of particle making is described below). [0042] Any manually or automatically operable mechanical, pneumatic, hydraulic, or electrical molding device capable of subjecting the cohesive body to pressure is suitable for use in the method of the present invention. In the production of various embodiments of the present invention a molding device may be utilized that is capable of applying a pressure of from about 689 kPa (100 pounds per square inch (psi)) to about 689,000 kPa (100,000 psi) for a time period of from 25 about 2 seconds to about 48 hours. Preferably, the molding device used in the method of the present invention will be capable of applying a pressure of from about 6,895 kPa (1000 psi) to about 207,000 kPa (30,000 psi) for a time period of from about 10 seconds to about 60 minutes. More preferably, the molding device used in the method of the present invention will be capable of applying a pressure of from about 21,000 kPa (3,000 psi) to about 172,000 kPa (25,000 psi) for a time period of from about one minute to about ten minutes. 30 [0043] Compression molding devices suitable for use in the practice of the method of the present invention are generally known. Suitable devices may be manufactured by a number of vendors according to provided specifications, such as desirable pressure, desired materials for formulation, desired pressure source, desired size of the moldable and resulting molded device, and the like. For example, Gami Engineering, located in Mississauga, Ontario manufactures compression molding devices to specifications provided by the customer. Additionally, many compression molding devices are com- 35 mercially available. See U.S. Patent No. 6,342,250 and U.S. App. No. 09/796,170, and U.S. Provisional Application Serial No. 60/376,136, filed on April 29, 2002, which are incorporated by reference herein, for a description of one type of compression molding device that may be utilized in the process of the present invention. [0044] The compression molding devices utilized in the process of the present invention are generally capable of applying from about 689 kPa (100 psi) to about 689,000 kPa (100,000 psi) for a time period of from about 2 seconds to 40 about 48 hours, preferably capable of applying from about 6,895 kPa (1000 psi) to about 207,000 kPa (30,000 psi) for a time period of from about 10 seconds to about 60 minutes, and more preferably, capable of applying a pressure of from about 21,000 kPa (3000 psi) to about 172,000 kPa (25,000 psi) for a time period of from about 1 minute to about 10 minutes. [0045] The resulting biomatrix material preferably has as little solvent as possible while still being cohesive and pos- 45 sessing the desired features relevant to the device’s function, e.g., preferably a solvent content of from about 5% to about 60%, more preferably a solvent content of from about 10% to about 50% and most preferably 20% to 40%. It is found that when a biomatrix material of the present invention includes one or more pharmacologically active agents, the partial drying of the film to form a cohesive body and subsequent compressing of the cohesive body, forces more solvent out of the body, thereby producing a resulting biomatrix material that has a significantly higher concentration of phar- 50 macologically active agents relative to other components of the material. As a result of the substantially uniform dispersion of a greater concentration of pharmacologically active agent, a sustained, controlled release of the pharmacologically active agent is achieved, while reducing the initial high concentration effects that can be associated with other devices that include pharmacologically active agents. [0046] The biocompatibility and tissue response to such biomatrix material has been shown to be favorable in related 55 cardiovascular and drug delivery research. The biocompatibility of the protein matrix material has been demonstrated through several studies. In one study, cylindrical implants (3.5 mm X 8 mm) were implanted next to the sciatic nerve in a rat model. The implants were left in place up to 12 weeks. The biomatrix material used in this study was designed to not react with any cells, but to demonstrate the surrounding tissue response to the material. The implants that were

11 EP 1 528 894 B1

dissected and histological evaluations of the surrounding tissues were performed. The sections were stained with Mas- son’s trichrome to highlight the connective tissue. A mild connective tissue formation around the implant was observed. The connective tissue around the implant serves to hold the implants in place. The amount of tissue observed at the 12 week time period was less than 20 microns compared to the several hundred microns that normally hold nerves in place. 5 A histology slide from the sciatic nerve study is shown in Figure 1. [0047] A second study was conducted where 1 mg size biomatrix cylinders were implanted into the epidural space of rats at lumbar vertebrae 2. All implants were sterilized prior to implantation by means of gamma irradiation. This study showed that the implants could deliver an opiate drug for 10 days in vitro and caused an analgesic effect for 10 days in rats receiving these epidural implants. All rats returned to normal behavior and pre-baseline analgesic testing scores. 10 Hind limb strength was also tested in these animals and no effects were observed for the entire course of study. The implants and the surrounding tissue underwent histological assessment after explanted. The sections were stained with H & E. A histological section from the study (2 weeks post implantation) is shown below in Figure 2. The biomatrix materials were found to be biocompatible and demonstrate a favorable tissue response. [0048] Many other biocompatibility studies have been completed. Subcutaneous implants in rats (3.5mm i.d. 8mm 15 tong, n=6 per time point) at 1, 2, 4, 6, 8 and 12 weeks were evaluated histologically using H & E staining and Masson’s trichrome staining. It was found that acute inflammatory reaction to the biomatrix implants resolved within 3 62 days and that chronic inflammatory reaction resolved in 764 days. There were only occassional giant cells observed in a small fraction of the rats for the 2, 4, 6 week time points. Many macrophages were observed penetrating the surface of the matrix as early as 1 week. 20 [0049] The final area of research that is directly applicable to the present invention is the ability of cells to grow on the material. One study demonstrated this by showing fibroblasts attaching to various biomatrix embodiments containing collagen and elastin proteins. A sample of the study results are shown below in Figure 3 (The bar in each quadrant is 7.5, 4.3, 10.0 and 5.0 pm shown in top left, top right, lower left and lower right figures, respectively). [0050] The activity of an attached cell such as these fibroblasts can be altered by changes in the fabrication technique 25 (compression & cross-linking) and composition of the biomatrix materials. Additionally, cells can take on different shapes depending upon the type of biomatrix material they contact. The ability of cells to take on different shapes is indicative of their ability to respond to their environment for specialized cell functions (e.g., differentiation, proliferation). [0051] The combined preliminary work aimed at the processing, the biocompatibility, the drug release, and the cell attachment capabilities demonstrate that the containment sleeve and particles of the present invention can be applied 30 as materials for numerous clinical applications including many areas of orthopaedic surgery for bone and cartilage repair. [0052] The processing of the material can be tailored for many specific applications and forms. For application to orthopedic products, a composite material can be generated. For example, the composite may include a base protein matrix including hydroxyapatite and collagen. However, it is noted that other proteins and/or biocompatible materials, such as minerals and pharmacologically active agents may be utilized in base protein matrix. The composite matrix 35 material may then be processed into the fixation system of the present invention comprising a containment sleeve and/or particles. [0053] As previously suggested, embodiments of the fixation device of the present invention may utilize two constructs of the biomatrix material, sheets and particles. These two constructs can be ut ilized as a fixation device either separately or in concert with each other. A number of embodiments of the first construct include a sheet form of the biomatrix 40 material which may be further formed into a containment and fixation sleeve. In various embodiments of the present invention, sheets, as previously proposed, may be manufactured using a compression molding process while controlling the input materials to make a sheet of a defined thickness and consistent structure. The sheets utilized may be of any thickness. However, sheets generally range from .01- 50 mm thick and preferably .20-10 mm thick. [0054] The biomatrix sheets utilized in the containment sleeve of some embodiments of the present invention may 45 include one or more sides that are crosslinked to provide additional beneficial characteristics and one or more sheets can be incorporated together in a laminar form. Crosslinking of the sleeve may be performed by any means known in the art such as exposure to chemical crosslinking agents like glutaraldehyde, p-Azidobenzolyl Hydazide, N-5-Azido 2- nitrobenzoyloxysuccinimide, N-Succinimidyl 6-[4’azido-2’nitro-phenylamino]hexanoate and 4-[p-Azidosalicylamido] butylamine, ultraviolet light or other radiation sources like ultrasound or gamma rays. 50 [0055] Figure 4 depicts one embodiment of the containment sleeve of the present invention. This embodiment of the present invention includes one or more sheets of the biomatrix material made from collagen-elastin proteins. It is noted that two or more sheets of different material may be utilized as a laminate to provide the attributes desired depending on the injury. The sheet or sheets can be fastened together at the ends with various suitable fastening devices, such as adhesives, staples, cerclages, screws, plates and/or sutures so as to create an enclosure, such as a tube or hollowed 55 block. The adhered ends of the sheet may butt up to each other or be overlapped during fastening. The embodiment in Figure 4 illustrates how well nylon suture can be used to hold the sheets, together in a tubular assembly. [0056] Further studies with the biomatrix material shows that the material is permeable to small solutes and solutions but does not leak fluid even around suture holes. The biomatrix material has been shown to be quite elastic and strong

12 EP 1 528 894 B1

(>50% elasticity possible in mechanical testing with over 34 kPa (5 psi) ultimate tensile strength in 0.2mm thick material). [0057] Figure 5 depicts another embodiment of containment sleeve which includes the biomatrix material. The sleeve illustrated in Figure 5 (approximately 0.2 mm thick) was centered over the ends of polyethylene tubing and fixed with glue and clamped down with silk suture. The material was then tested for strength and flexibility. It was found that the 5 containment sleeve of this embodiment was quite compliant, strong and flexible. This test and subsequent tests showed that ultimate tensile strength exceeded 69 kPa (10 psi) and that the material was >50% elastic without losing strength. [0058] Two specific embodiments of the composition are generally comprised of hydroxyapatite and a protein or proteoglycan such as collagen or collagen-elastin-heparin. The first includes 10-20% hydroxyapatite, preferably 15% hydroxyapatite by weight and the second includes 25-35% hydroxyapatite, preferably 30% hydroxyapatite by weight. 10 However, hydroxyapatite can be incorporated in higher or lower amounts ranging 0%-75% by weight and preferably from 10%-40% by weight. [0059] As previously suggested the biomatrix material is formed into a sheet and is capable of being placed around a fractured bone. For example sheets made of polyurethane, polytetrafluoroethylene, polyvinylalcohol, polylactic acid or any other biocompatible material may be formed into a sleeve that may be utilized in the fixation device of the present 15 invention. It is noted that the material utilized to prepare the containment sleeve of the present invention may be comprised of any biocompatible polymeric material, including but not limited to proteins. Furthermore the biocompatible polymeric material may include pharmacologically active agents, which are delivered to the injured or diseased site. [0060] The containment sleeve of the present invention may be produced to remodel with and/or resorb into the surrounding tissue or remain positioned around the fractured area after it has mended. Also, the containment sleeve 20 may function by itself or in cooperation with the particles described below. [0061] In operation of one embodiment of the present invention, a fracture fixation sleeve is constructed from a sheet formedto properdimensions orcut tosize from a sheet ofbiomatrix material; for example a sheetmade with hydroxyapatite and collagen. However, as previously mentioned a sheet comprised of any biocompatible material may be utilized. Once the biomatrix material is available in a sheet of proper size and shape, it can be positioned around the fracture area or 25 other injured area, such as a nerve fractured or damaged area like the spinal cord to function as a containment sleeve for delivery of therapeutic biochemicals or containment from undesirable components of the body. As previously noted, other biochemicals and/or pharmacologically active agents may be utilized in the present invention. The sleeve may be secured by a variety of fastening devices, including but not limited to, staples, cerclages, screws, plates, adhesives, bindings and/or any other suitable fasteners for holding the sleeve in place around the fracture site. It is noted that the 30 staples, cerclages, screws, plates, adhesives, bindings and/or any other suitable fasteners may also be made of a biomatrix material of sufficient strength and rigidity to penetrate the sleeve material and/or fractured bone to secure the sleeve in place. Once the containment sleeve is placed into position over the injured site, it can provide therapeutic relief to the injury and promote proper healing. It is noted that the containment and fixation sleeve of the present invention may also be utilized for implanted prosthetic device implantation, such as the implantation of knee and hip prosthetics. 35 The containment sleeve can be of assistance in prosthetic implantation to contain wear debris and to facilitate integration of the surrounding bone and tissue (e.g. cartiledge and bone integration) with the prosthetic device. [0062] The fixation device of the present invention may also comprise the biomatrix material constructed into particles of any size. An illustration of an embodiment of the particles of the present invention is depicted in Figure 6. In one embodiment of the present invention the particles are produced utilizing the biomatrix material previously described. 40 Alternatively, particles may be derived from a biocompatible protein material produced by applying heat, freeze drying techniques such as liquid nitrogen or dry ice freeze drying, vacuum or other similar drying techniques to eliminate excess solvent from the cohesive body rather than compressing it. These alternative techniques remove enough solvent from the cohesive body to provide for the production of distinct particles, but do not eliminate too much solvent wherein the interaction of solvent and protein is lost. Generally, many particle embodiments of the present invention are substantially 45 insoluablethereby allowing themto be integrated and remodeledby the host tissue rather thanbe consumed and excreted. [0063] One example of an alternative method to make particles is by heating the cohesive body and then processing the resulting cohesive body into particles. In such a method the cohesive body may be heated at temperatures ranging from 0°-150° C, preferably 20°-120° C and most preferably 40°-100° C. Generally, the heating process may be conducted for approximately 5 minutes to 48 hours, preferably 1-24 hours and most preferably 2-6 hours. Embodiments of the 50 resulting cohesive body following heating, or any of the alternative techniques identified above, usually have as little solvent as possible while still being cohesive and possessing the desired features relevant to the device’s function, e.g., preferably a solvent content of from about 5% to about 60%, more preferably a solvent content of from about 10% to about 50% and most preferably 20% to 40%. [0064] Before the biomatrix material or biocompatible protein material is processed into particles it may also be 55 crosslinked to provide additional beneficial characteristics. The optional step of crosslinking the biomatrix material or biocompatibleprotein material may be performed by any meansknown in the art such as exposureto chemical crosslinking agents like glutaraldehyde, p-Azidobenzolyl Hydazide, N-5-Azido 2-nitrobenzoyloxysuccinimide, N-Succinimidyl 6-[4’azi- do-2’nitro-phenylamino]hexanoate and 4-[p-Azidosalicylamido] butylamine, ultraviolet light or other radiation sources

13 EP 1 528 894 B1

like ultrasound or gamma ray. [0065] The particles of the present invention are generally prepared by further processing the biomatrix material or biocompatible protein material produced by the alternative methods described above. Figure 6 depicts embodiments of the biocompatible protein particles of the present invention. One method of producing the particles utilized in products 5 of the present invention includes the crushing, cutting, pulverizing or grinding of the biomatrix material and/or biocom- patible protein material. [0066] Generally, the particles may vary in size but are normally approximately 10 nm - 5 mm, preferably 500 nm -2.5 mm and more preferably 1-1000 um. A characteristic of the particles produced from the biocompatible protein material is that they no longer aggregate when in the particulate state. Furthermore, prior studies have demonstrated that the 10 particles do not aggregate in saline and are easily delivered through small gauge needles. The particles can be made to disassociate at very slow or fast rates in aqueous solutions. [0067] After the particles are formed using the various methods described above, they are characterized for their basic structure. First the particles may be segregated using a series of pharmaceutical drug sieves. Additional characterization of the particles will consist of verification of the shape and size of the particles using light and electron microscopy (Fig.6 ). 15 [0068] The particles may be utilized as a fixation device by administering them to the fractured bone or other fractured site such as the spinal cord by a variety of administration techniques. Various embodiments of the present invention include the ability to incorporate both hydroxyapatite and collagen into the particles of the present invention, which are administered to the fracture site. One administration procedure of the present invention includes the injection of the particles in a slurry into the injured site by syringe. This procedure provides for the particles being placed in solution for 20 delivery. Saline is a solution that may be employed to prepare the slurry, but any biocompatible solution may be utilized. Saline has been selected for the initial material for several reasons including its common use in medical procedures and its availability in a sterile form. The slurry may be delivered in any way known in the art including delivery through a needle. Any gauge needle may be utilized to deliver the slurry containing the particles of the present invention, including but not limited to 12-26 gauge needles. 25 [0069] Alternatively, the particles of the present invention may also be placed into position without utilizing needles, such as when the particles are too large to fit through a needle. These particles are typically 0.5-5mm in size, more typically 1-25mm. In such a procedure the particles may be surgically implanted and packed into and/or around the injured site. For example, particles may be surgically packed into and around a bone fracture and subsequently sealed into position by the host tissue surrounding the fractured bone. 30 [0070] Finally, an additional embodiment of the fixation device of the present invention includes the utilization of both the containment sleeve and the particles. The method to use the fixation system of the present invention at an injury or deterioration site, such as a fracture generally comprises positioning the containment sleeve completely or partially around the fracture site. Next, either 1) particles are placed in the sleeve and the sleeve is secured into position; or 2) the sleeve is secured and particles or a particle slurry is injected into the secured sleeve. As previously mentioned, a 35 series of fixation devices including sutures, cerclages, staples, adhesives, plates, screws, bindings, bands and any other fasteners may be utilized to attach the sheet of biomatrix material thereby wrapping around the bone ends to make a tube or other shaped enclosure. The biomatrix enclosure or containment sleeve acts to contain healing bone particles, such as the particles of the present invention, bone fragments, or the like, within the tube. The biomatrix enclosure or containment sleeve also acts to maintain the beneficial healing components generated by the bone site within the site 40 and further keeps detrimental components (e.g. soft tissue and/or inflammatory cells) that may inhibit healing out of the site. As previously indicated, additional drugs or bone enhancing growth factors (e.g. bone morphogenic protein, BMP) may be incorporated into the biomatrix material of the containment sleeve and/or particles that will increase the rate of bone and tissue growth and bone and tissue healing, enhance cell attachment and reduce pain. [0071] In another embodiment of the present invention, the implant system comprises a fracture fixation sleeve con- 45 structed from a sheet cut to size from a sheet of biomatrix material, for example a sheet made with hydroxyapatite and collagen/elastin or hydroxyapatite and collagen-elastin-heparin. Once produced, the hydroxyapatite and protein matrix sleeve is wrapped around a fracture site and secured into place. The sleeve may be secured by a variety of fastening devices, including but not limited to, staples, cerclages, screws, plates, adhesives, bindings, sutures and/or any other suitable fasteners for holding the sleeve in place around the fracture site. It is noted that the staples, cerclages, screws, 50 plates, adhesives, bindings and/or any other suitable fasteners may also be made of a biomatrix material of sufficient strength and rigidity to penetrate the sleeve material and/or fractured bone to secure the sleeve in place. Particles fashioned from the biomatrix material or biocompatible protein are then injected and/or placed into the sleeve. It is noted that alternatively the particles of the present invention may be packed in or around the fracture site before the containment sleeve is administered to the site. The particles in conjunction with the sleeve enables bone to heal across defects 55 through osteoconductive regeneration of bone tissue directed and contained by the sleeve and induced by the particles. [0072] An illustration of utilizing the fracture fixation system of the present invention would be in the repair of a full- thickness segmental defect as depicted in the animal model of Figure 7. The defect is stabilized under aseptic conditions with a polyacetyl plate and Kirchner wires. The animal model is based off of a study conducted previously by the MMRF

14 EP 1 528 894 B1

Orthopaedic Biomechanics Lab. [0073] In treating such a segmental defect model as depicted in Figure 7, an embodiment of the fixation system of the present invention may be administered to provide assistance in the mending of the fracture. Figure 8 illustrates the process of administering the fixation system of the present invention to a defect similar to the defect depicted in Figure 7. 5 [0074] In Figure 8 the defect includes a non-union fracture (A). Large particles are packed in and around the fracture (B). Next, a containment and fixation sleeve of the present invention, transparent for schematic, is wrapped around the fracture and banded to the bone with sutures (C). Following banding of the containment sleeve to the bone, a slurry of particles is injected inside the containment sleeve, transparent for schematic (D). Finally, the containment sleeve is sealed and secured around the around bone fracture by adhereing the ends of the containment sleeve to themselves (E). 10

Claims

1. A biomatrix containment and fixation system for treatment of a fracture or damage to a part of the body, comprising 15 a biocompatible protein, a biocompatible solvent and a pharmacologically active agent, and a containment and fixation sleeve and a plurality of protein particles administered within said sleeve, said protein particles including one or more biocom- patible proteins combined with one or more biocompatible solvents and one or more pharmacologically active agents, characterised in that the containment and fixation sleeve is formed by compressing a cohesive body to form a 20 biomatrix material, the cohesive body including one or more biocompatible proteins combined with one or more biocompatible solvents and optionally one or more pharmacologically active agents such that the cohesive body has a solvent content of about 10% to 80% by weight prior to compression, the cohesive body is compressed at a pressure of about 689 kPa (100 psi) to about 689,000 kPa (100,000 psi) to form the sleeve of biomatrix material having a solvent content of about 5% to 60% by weight, wherein the solvent content of the biomatrix material is less 25 than the solvent content of the cohesive body, said sleeve having two ends adhered together with a fastening device to form an enclosure.

2. The biomatrix containment and fixation system of claim 1 wherein the biocompatible proteins are selected from the group consisting of elastin, collagen, albumin, ovalbumin, keratin, fibronectin, silk, silk fibroin, actin, myosin, fibrin- 30 ogen, thrombin, aprotinin, antithrombin III, elastinlike blocks, silklike blocks, collagenlike blocks, lamininlike blocks, fibronectinlike blocks and silklike, elastinlike blocks, collagen-heparin, collagen-elastin-albumin-heparin, collagen- albumin, collagen-elastin-heparin and collagen-chondroitin.

3. The biomatrix containment and fixation system of claim 1 wherein the biocompatible solvent is selected from the 35 group consisting of water, dimethyl sulfoxide (DMSO), biocompatible alcohols, biocompatible acids, oils and bio- compatible glycols.

4. The biomatrix containment and fixation system of claim 1 wherein the one or more pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, antipsychotic agents, angiogenic growth factors, 40 bone mending biochemicals, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anti- coagulants agents, genetic material, antithrombolytic agents, anticancer agents, anti-Parkinson agents, antiepileptic agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents, hypoglycemic agents, antihistamine agents, chemoattractants, neutraceu- ticals, antiobesity, smoking cessation agents, obstetric agents and antiasmatic agents. 45 5. The biomatrix containment and fixation system of claim 4 wherein the pharmacologically active agents are hydroxya- patite, bone morphogenic protein VEGF or combinations thereof.

6. The biomatrix containment and fixation system of claim 1 wherein the fastening device is one or more devices 50 selected from the group consisting of staples, cerclages, screws, plates, adhesives, bindings and sutures.

7. The biomatrix containment and fixation system of claim 1, wherein the sleeve, particles or both further comprise one or more biocompatible additives.

55 8. The biomatrix containment and fixation system of claim 7 wherein the one or more biocompatible additives are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), polycaprolactone, polyethylene oxide, polyethylene glycol, poly(vinyl chlo- ride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid,

15 EP 1 528 894 B1

polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate, polyhydroxyvalerate, poly(ethylene oxide), poly ortho es- ters, poly (amino acids), polycyanoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, 5 silicone rubber, and copolymers of these.

9. The biomatrix containment and fixation system of claim 1 wherein all or a portion of the sleeve and particles are crosslinked with one or more crosslinking agents.

10 10. The biomatrix containment and fixation system of claim 9 wherein the one or more crosslinking agents are selected from the group consisting of glutaraldehyde, p-Azidobenzolyl Hydazide, N-5-Azido 2-nitrobenzoyloxysuccinimide, N-Succinimidyl 6-[4’azido-2’nitro-phenylamino]hexanoate and 4-[p-Azidosalicylamido] butylamine.

11. The biomatrix containment and fixation system of claim 1 wherein the particles have a size of approximately 10nm 15 to 5mm.

12. Use of one or more biocompatible proteins combined with one or more biocompatible solvents for the manufacture of a biomatrix containment and fixation system according to claim 1

20 13. Use of claim 12, wherein said sleeve has two ends adhered together with a fastening device to form an enclosure.

14. Use of claim 12 wherein the biocompatible proteins are selected from the group consisting of elastin, collagen, albumin, ovalbumin, keratin, fibronectin, silk, silk fibroin, actin, myosin, fibrinogen, thrombin, aprotinin, antithrombin III, elastinlike blocks, silklike blocks, collagenlike blocks, lamininlike blocks, fibronectinlike blocks and silklike, elastin - 25 like blocks, collagen-heparin, collagen-elastin-albumin-heparin, collagen-albumin, collagen-elastin-heparin and col- lagen-chondroitin.

15. Use of claim 12 wherein the biocompatible solvent is selected from the group consisting of water, dimethyl sulfoxide (DMSO), biocompatible alcohols, biocompatible acids, oils and biocompatible glycols. 30 16. Use of claim 12 wherein the sleeve includes one or more pharmacologically active agents and the one or more pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, antipsychotic agents, angiogenic growth factors, bone mending biochemicals, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anticoagulants agents, genetic material, antithrombolytic agents, anticancer agents, 35 anti-Parkinson agents, antiepileptic agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents, hypoglycemic agents, antihistamine agents, chemoattractants, neutraceuticals, antiobesity, smoking cessation agents, obstetric agents and antiasmatic agents.

17. Use of claim 16 wherein the pharmacologically active agents are hydroxyapatite, bone morphogenic protein, VEGF 40 or combinations thereof.

18. Use of claim 12 wherein the fastening device is one or more devices selected from the group consisting of staples, cerclages, screws, plates, adhesives, bindings and sutures.

45 19. Use of claim 12 further comprising one or more biocompatible additives.

20. Use of claim 19 wherein the one or more biocompatible additives are selected from the group consisting of epoxiel, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), poly- caprolactone, polyethylene oxide, polyethylene glycol, poly(vinyl chloride), polylactic acid, polyglycolic acid, poly- 50 propylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3- bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxy- butyrate, polyhydroxyvalerate, poly(ethylene oxide), poly ortho esters, poly (amido acids), polycyanoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl- based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, and copolymers of these. 55 21. Use of claim 12 further comprising administering a plurality of particles into the sleeve, said particles including one or more biocompatible proteins combined with one or more biocompatible solvents and one or more pharmacolog- ically active agents.

16 EP 1 528 894 B1

22. Use of claim 21 wherein the particles have a size of approximately 10nm to 5mm.

23. Use of claim 21 wherein the biocompatible proteins are selected from the group consisting of elastin, collagen, albumin, ovalbumin, keratin, fibronectin, silk, silk fibroin, actin, myosin, fibrinogen, thrombin, aprotinin, antithrombin 5 III, elastinlike blocks, silklike blocks, collagenlike blocks, lamininlike blocks, fibronectinlike blocks and silklike, elastin - like blocks, collagen-heparin, collagen-elastin-albumin-heparin, collagen-albumin, collagen-elastin-heparin and col- lagen-chondroitin.

24. Use of claim 21 wherein the biocompatible solvent is selected from the group consisting of water, dimethyl sulfoxide 10 (DMSO), biocompatible alcohols, biocompatible acids, oils and biocompatible glycols.

25. Use of claim 21 wherein the one or more pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, antipsychotic agents, angiogenic growth factors, bone mending biochemicals, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anti-coagulants agents, genetic material, an- 15 tithrombolytic agents, anticancer agents, anti-Parkinson agents, antiepileptic agents, anti-inflammatory agents, an- ticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents, hypoglycemic agents, antihistamine agents, chemoattractants, neutraceuticals, antiobesity, smoking cessation agents, obstetric agents and antiasmatic agents.

20 26. Use of claim 25 wherein the pharmacologically active agents are hydroxyapatite, bone morphogenic protein VEGF or combinations thereof.

27. Use of claim 21 further comprising one or more biocompatible additives.

25 28. Use of claim 27 wherein the one or more biocompatible additives are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), poly- caprolactone, polyethylene oxide, polyethylene glycol, poly(vinyl chloride), polylactic acid, polyglycolic acid, poly- propylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxy- 30 butyrate, polyhydroxyvalerate, poly(ethylene oxide), poly ortho esters, poly (amino acids), polycyanoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl- based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, and copolymers of these.

35 Patentansprüche

1. Biomatrix-Halte- und Fixiersystem für die Behandlung einer Fraktur oder Schädigung eines Körperteils, umfassend ein biokompatibles Protein, ein biokompatibles Lösungsmittel und einen pharmakologischen Wirkstoff und eine Halte- und Fixierungshülse und eine Vielzahl in die Hülse eingebrachter Proteinpartikel, wobei die Proteinpartikel 40 ein oder mehrere biokompatible Proteine in Kombination mit einem oder mehreren biokompatiblen Lösungsmitteln und einem oder mehreren pharmakologischen Wirkstoffen enthalten, dadurch gekennzeichnet, dass die Halte- und Fixierungshülse durch Komprimieren eines kohäsiven Körpers zu einem Biomatrixmaterial gebildet wird, wobei der kohäsive Körper ein oder mehrere biokompatible Proteine in Kombination mit einem oder mehreren biokomp- atiblen Lösungsmitteln und gegebenenfalls einem oder mehreren pharmakologischen Wirkstoffen enthält, so dass 45 der zusammenhängende Körper einen Lösungsmittelgehalt von etwa 10 bis 80 Gew.-% vor der Kompression auf- weist, wobei der zusammenhängende Körper bei einem Druck von etwa 689 kPa (100 psi) bis etwa 689.000 kPa (100.000 psi) komprimiert wird, um die Hülse aus Biomatrixmaterial mit einem Lösungsmittelgehalt von etwa 5 bis 60 Gew.-% zu bilden, wobei der Lösungsmittelgehalt des Biomatrixmaterials geringer als der Lösungsmittelgehalt des zusammenhängenden Körpers ist, wobei die Hülse zwei Enden aufweist, die mittels einer Befestigungsvorrich- 50 tung miteinander verbunden sind, um eine Umhüllung zu bilden.

2. Biomatrix-Halte- und Fixiersystem nach Anspruch 1, wobei die biokompatiblen Proteine aus der Gruppe ausgewählt sind, welche aus Elastin, Kollagen, Albumin, Ovalbumin, Keratin, Fibronektin, Seide, Seidenfibroin, Aktin, Myosin, Fibrinogen, Thrombin, Aprotinin, Antithrombin III, elastinähnlichen Blöcken, seidenähnlichen Blöcken, kollagenähn- 55 lichen Blöcken, lamininähnlichen Blöcken, fibronektinähnlichen Blöcken und seidenähnlichen, elastinähnlichen Blö- cken, Kollagen-Heparin, Kollagen-Elastin-Albumin-Heparin, Kollagen-Albumin, Kollagen-Elastin-Heparin und Kol- lagen-Chondroitin besteht.

17 EP 1 528 894 B1

3. Biomatrix-Halte- und Fixiersystem nach Anspruch 1, wobei das biokompatible Lösungsmittel aus der Gruppe aus- gewählt ist, welche aus Wasser, Dimethylsulfoxid (DMSO), biokompatiblen Alkoholen, biokompatiblen Säuren, Ölen und biokompatiblen Glycolen besteht.

5 4. Biomatrix-Halte- und Fixiersystem nach Anspruch 1, wobei der eine oder die mehreren pharmakologischen Wirk- stoffe aus der Gruppe ausgewählt sind, welche aus Analgetika, Anästhetika, Antipsychotika, angiogenen Wachs- tumsfaktoren, knochenheilenden Biochemikalien, Steroiden, Antisteroiden, Corticosteroiden, Antiglaukommitteln, Mitteln gegen Alkoholabhängigkeit, Antikoagulanzien, genetischem Material, Antithrombotika, Mitteln gegen Krebs, Parkinsonmitteln, Antiepileptika, Antiphlogistika, Kontrazeptiva, Enzymsubstanzen, Zellen, Wachstumsfaktoren, an- 10 tiviralen Mitteln, antibakteriellen Mitteln, Antimykotika, hypoglykämischen Mitteln, Antihistaminika, chemischen Lock- stoffen, Nutrazeutika, Mitteln gegen Adipositas, Mitteln zur Raucherentwöhnung, obstetrischen Mitteln und Antias- thmatika besteht.

5. Biomatrix-Halte- und Fixiersystem nach Anspruch 4, wobei es sich bei den pharmakologischen Wirkstoffen um 15 Hydroxylapatit, knochenmorphognetisches Protein, VEGF oder Kombinationen davon handelt.

6. Biomatrix-Halte- und Fixiersystem nach Anspruch 1, wobei es sich bei der Befestigungsvorrichtung um eine oder mehrere Vorrichtungen handelt, die aus der Gruppe ausgewählt sind, welche aus Klammern, Cerclagen, Schrauben, Platten, Klebstoffen, Binden und Nähten besteht. 20 7. Biomatrix-Halte- und Fixiersystem nach Anspruch 1, wobei die Hülse, die Partikel oder beide ferner einen oder mehrere biokompatible Zusätze umfassen.

8. Biomatrix-Halte- und Fixiersystem nach Anspruch 7, wobei der eine oder die mehreren biokompatiblen Zusätze aus 25 der Gruppe, bestehend aus Epoxidharzen, Polyestern, Polyacrylaten, Nylon, Siliconen, Polyanhydrid, Polyurethan, Polycarbonat, Polytetrafluorethylen, Polycaprolacton, Polyethylenoxid, Polyethylenglycol, Polyvinylchlorid, Poly- milchsäure, Polyglycolsäure, Polypropylenoxid, Polyalkylenglycol, Polyoxyethylen, Sebacinsäure, Polyvinylalkohol, 2-Hydroxyethylmethacrylat, Polymethylmethacrylat, 1,3-Biscarboxyphenoxypropan, Lipiden, Phosphatidylcholin, Triglyceriden, Polyhydroxybutyrat, Polyhydroxyvalerat, Polyethylenoxid, Polyorthoestern, Polyaminosäuren, Poly- 30 cyanoacrylaten, Polyphosphazenen, Polysulfon, Polyamin, Polyamidoaminen, Fibrin, Graphit, flexiblem Fluorpoly- mer, isobutylbasierten Materialien, Isopropylstyrol, Vinylpyrrolidon, Celluloseacetatdibutyrat, Silikonkautschuk und Copolymeren derselben ausgewählt sind.

9. Biomatrix-Halte- und Fixiersystem nach Anspruch 1, wobei die Gesamtheit oder ein Teil der Hülse und der Partikel 35 mit einem oder mehreren Vernetzungsmitteln vernetzt sind.

10. Biomatrix-Halte- und Fixiersystem nach Anspruch 9, wobei das eine oder die mehreren Vernetzungsmittel aus der Gruppe ausgewählt sind, welche aus Glutaraldehyd, p-Azidobenzolylhydrazid, N-5-Azido-2-nitrobenzoyloxysucci- nimid, N-Succinimidyl-6-[4’-azido-2’-nitrophenylamino]hexanoat und 4-[p-Azidosalicylamido]butylamin besteht. 40 11. Biomatrix-Halte- und Fixiersystem nach Anspruch 1, wobei die Partikel eine Größe von ungefähr 10 nm bis 5 mm haben.

12. Verwendung eines oder mehrerer biokompatibler Proteine in Kombination mit einem oder mehreren biokompatiblen 45 Lösungsmitteln für die Herstellung eines Biomatrix-Halte- und Fixiersystems nach Anspruch 1.

13. Verwendung nach Anspruch 12, wobei die Hülse zwei Enden aufweist, die mittels einer Befestigungsvorrichtung miteinander verbunden sind, um eine Umhüllung zu bilden.

50 14. Verwendung nach Anspruch 12, wobei die biokompatiblen Proteine aus der Gruppe ausgewählt sind, welche aus Elastin, Kollagen, Albumin, Ovalbumin, Keratin, Fibronektin, Seide, Seidenfibroin, Aktin, Myosin, Fibrinogen, Throm- bin, Aprotinin, Antithrombin III, elastinähnlichen Blöcken, seidenähnlichen Blöcken, kollagenähnlichen Blöcken, lamininähnlichen Blöcken, fibronektinähnlichen Blöcken und seidenähnlichen, elastinähnlichen Blöcken, Kollagen- Heparin, Kollagen-Elastin-Albumin-Heparin, Kollagen-Albumin, Kollagen-Elastin-Heparin und Kollagen-Chondroitin 55 besteht.

15. Verwendung nach Anspruch 12, wobei das biokompatible Lösungsmittel aus der Gruppe ausgewählt ist, welche aus Wasser, Dimethylsulfoxid (DMSO), biokompatiblen Alkoholen, biokompatiblen Säuren, Ölen und biokompatiblen

18 EP 1 528 894 B1

Glycolen besteht.

16. Verwendung nach Anspruch 12, wobei die Hülse einen oder mehrere pharmakologische Wirkstoffe enthält und der eine oder die mehreren pharmakologischen Wirkstoffe aus der Gruppe ausgewählt sind, welche aus Analgetika, 5 Anästhetika, Antipsychotika, angiogenen Wachstumsfaktoren, knochenheilenden Biochemikalien, Steroiden, An- tisteroiden, Corticosteroiden, Antiglaukommitteln, Mitteln gegen Alkoholabhängigkeit, Antikoagulanzien, geneti- schem Material, Antithrombotika, Mitteln gegen Krebs, Parkinsonmitteln, Antiepileptika, Antiphlogistika, Kontrazep- tiva, Enzymsubstanzen, Zellen, Wachstumsfaktoren, antiviralen Mitteln, antibakteriellen Mitteln, Antimykotika, hy- poglykämischen Mitteln, Antihistaminika, chemischen Lockstoffen, Nutrazeutika, Mitteln gegen Adipositas, Mitteln 10 zur Raucherentwöhnung, obstetrischen Mitteln und Antiasthmatika besteht.

17. Verwendung nach Anspruch 16, wobei es sich bei den pharmakologischen Wirkstoffen um Hydroxylapatit, kno- chenmorphogenetisches Protein, VEGF oder Kombinationen davon handelt.

15 18. Verwendung nach Anspruch 12, wobei es sich bei der Befestigungsvorrichtung um eine oder mehrere Vorrichtungen handelt, die aus der Gruppe ausgewählt sind, welche aus Klammern, Cerclagen, Schrauben, Platten, Klebstoffen, Binden und Nähten besteht.

19. Verwendung nach Anspruch 12, die ferner einen oder mehrere biokompatible Zusätze umfasst. 20 20. Verwendung nach Anspruch 19, wobei der eine oder die mehreren biokompatiblen Zusätze aus der Gruppe, be- stehend aus Epoxidharzen, Polyestern, Polyacrylaten, Nylon, Siliconen, Polyanhydrid, Polyurethan, Polycarbonat, Polytetrafluorethylen, Polycaprolacton, Polyethylenoxid, Polyethylenglycol, Polyvinylchlorid, Polymilchsäure, Poly- glycolsäure, Polypropylenoxid, Polyalkylenglycol, Polyoxyethylen, Sebacinsäure, Polyvinylalkohol, 2-Hydroxyethyl- 25 methacrylat, Polymethylmethacrylat, 1,3-Biscarboxyphenoxypropan, Lipiden, Phosphatidylcholin, Triglyceriden, Po- lyhydroxybutyrat, Polyhydroxyvalerat, Polyethylenoxid, Polyorthoestern, Polyaminosäuren, Polycyanoacrylaten, Polyphosphazenen, Polysulfon, Polyamin, Polyamidoaminen, Fibrin, Graphit, flexiblem Fluorpolymer, isobutylba- sierten Materialien, Isopropylstyrol, Vinylpyrrolidon, Celluloseacetatdibutyrat, Silikonkautschuk und Copolymeren derselben ausgewählt sind. 30 21. Verwendung nach Anspruch 12, die ferner das Einbringen einer Vielzahl von Partikeln in die Hülse umfasst, wobei die Partikel ein oder mehrere biokompatible Proteine in Kombination mit einem oder mehreren biokompatiblen Lösungsmitteln und einem oder mehreren pharmakologischen Wirkstoffen enthalten.

35 22. Verwendung nach Anspruch 21, wobei die Partikel eine Größe von ungefähr 10 nm bis 5 mm haben.

23. Verwendung nach Anspruch 21, wobei die biokompatiblen Proteine aus der Gruppe ausgewählt sind, welche aus Elastin, Kollagen, Albumin, Ovalbumin, Keratin, Fibronektin, Seide, Seidenfibroin, Aktin, Myosin, Fibrinogen, Throm- bin, Aprotinin, Antithrombin III, elastinähnlichen Blöcken, seidenähnlichen Blöcken, kollagenähnlichen Blöcken, 40 lamininähnlichen Blöcken, fibronektinähnlichen Blöcken und seidenähnlichen, elastinähnlichen Blöcken, Kollagen- Heparin, Kollagen-Elastin-Albumin-Heparin, Kollagen-Albumin, Kollagen-Elastin-Heparin und Kollagen-Chondroitin besteht.

24. Verwendung nach Anspruch 21, wobei das biokompatible Lösungsmittel aus der Gruppe ausgewählt ist, welche 45 aus Wasser, Dimethylsulfoxid (DMSO), biokompatiblen Alkoholen, biokompatiblen Säuren, Ölen und biokompatiblen Glycolen besteht.

25. Verwendung nach Anspruch 21, wobei der eine oder die mehreren pharmakologischen Wirkstoffe aus der Gruppe ausgewählt sind, welche aus Analgetika, Anästhetika, Antipsychotika, angiogenen Wachstumsfaktoren, knochen- 50 heilenden Biochemikalien, Steroiden, Antisteroiden, Corticosteroiden, Antiglaukommitteln, Mitteln gegen Alkohol- abhängigkeit, Antikoagulanzien, genetischem Material, Antithrombotika, Mitteln gegen Krebs, Parkinsonmitteln, Antiepileptika, Antiphlogistika, Kontrazeptiva, Enzymsubstanzen, Zellen, Wachstumsfaktoren, antiviralen Mitteln, antibakteriellen Mitteln, Antimykotika, hypoglykämischen Mitteln, Antihistaminika, chemischen Lockstoffen, Nutra- zeutika,Mitteln gegen Adipositas, Mitteln zurRaucherentwöhnung, obstetrischen Mitteln und Antiasthmatika besteht. 55 26. Verwendung nach Anspruch 25, wobei es sich bei den pharmakologischen Wirkstoffen um Hydroxylapatit, kno- chenmorphogenetisches Protein, VEGF oder Kombinationen davon handelt.

19 EP 1 528 894 B1

27. Verwendung nach Anspruch 21, die ferner einen oder mehrere biokompatible Zusätze umfasst.

28. Verwendung nach Anspruch 27, wobei der eine oder die mehreren biokompatiblen Zusätze aus der Gruppe, be- stehend aus Epoxidharzen, Polyestern, Polyacrylaten, Nylon, Siliconen, Polyanhydrid, Polyurethan, Polycarbonat, 5 Polytetrafluorethylen, Polycaprolacton, Polyethylenoxid, Polyethylenglycol, Polyvinylchlorid, Polymilchsäure, Poly- glycolsäure, Polypropylenoxid, Polyalkylenglycol, Polyoxyethylen, Sebacinsäure, Polyvinylalkohol, 2-Hydroxyethyl- methacrylat, Polymethylmethacrylat, 1,3-Biscarboxyphenoxypropan, Lipiden, Phosphatidylcholin, Triglyceriden, Po- lyhydroxybutyrat, Polyhydroxyvalerat, Polyethylenoxid, Polyorthoestern, Polyaminosäuren, Polycyanoacrylaten, Polyphosphazenen, Polysulfon, Polyamin, Polyamidoaminen, Fibrin, Graphit, flexiblem Fluorpolymer, isobutylba- 10 sierten Materialien, Isopropylstyrol, Vinylpyrrolidon, Celluloseacetatdibutyrat, Silikonkautschuk und Copolymeren derselben ausgewählt sind.

Revendications 15 1. Système de fixation et de confinement de matrice biologique pour le traitement d’une fracture ou d’une lésion d’une partie du corps, comprenant une protéine biocompatible, un solvant biocompatible et un agent pharmacologiquement actif, et une gaine de fixation et de confinement, et 20 une pluralité de particules protéiques administrées dans ladite gaine, lesdites particules protéiques comprenant une ou plusieurs protéines biocompatibles combinées avec un ou plusieurs solvants biocompatibles et un ou plusieurs agents pharmacologiquement actifs, caractérisé en ce que la gaine de fixation et de confinement est formée par compression d’un corps cohésif pour former un matériau de matrice biologique, le corps cohésif comprenant une ou plusieurs protéines biocompatibles 25 combinées avec un ou plusieurs solvants biocompatibles et éventuellement un ou plusieurs agents pharmacologi- quement actifs, de sorte que le corps cohésif ait une teneur en solvant d’environ 10 % à 80 % en poids avant la compression, le corps cohésif étant comprimé à une pression d’environ 689 kPa (100 psi) à environ 689 000 kPa (100 000 psi) pour former la gaine de matériau de matrice biologique ayant une teneur en solvant d’environ 5 % à 60 % en poids, la teneur en solvant du matériau de matrice biologique étant inférieure à la teneur en solvant du 30 corps cohésif, ladite gaine ayant deux extrémités qui adhèrent l’une à l’autre avec un dispositif de fixation pour former une enceinte.

2. Système de fixation et de confinement de matrice biologique selon la revendication 1, dans lequel les protéines biocompatibles sont choisies dans le groupe constitué par l’élastine, le collagène, l’albumine, l’ovalbumine, la ké- 35 ratine, la fibronectine, la soie, la fibroïne de soie, l’actine, la myosine, le fibrinogène, la thrombine, l’aprotinine, l’antithrombine III, les blocs de type élastine, les blocs de type soie, les blocs de type collagène, les blocs de type laminine, les blocs de type fibronectine et les blocs de type soie, de type élastine, le collagène-héparine, le collagène- élastine-albumine-héparine, le collagène-albumine, le collagène-élastine-héparine et le collagène-chondroïtine.

40 3. Système de fixation et de confinement de matrice biologique selon la revendication 1, dans lequel le solvant bio- compatible est choisi dans le groupe constitué par l’eau, le diméthylsulfoxyde (DMSO), les alcools biocompatibles, les acides biocompatibles, les huiles et les glycols biocompatibles.

4. Système de fixation et de confinement de matrice biologique selon la revendication 1, dans lequel le ou les agents 45 pharmacologiquement actifs sont choisis dans le groupe constitué par les analgésiques, les anesthésiques, les agents antipsychotiques, les facteurs de croissance angiogéniques, les agents biochimiques de réparation osseuse, les stéroïdes, les antistéroïdes, les corticostéroïdes, les agents antiglaucomateux, les agents anti-alcool, les agents anticoagulants, les matières génétiques, les agents antithrombolytiques, les agents anticancéreux, les agents anti- Parkinson, les agents antiépileptiques, les agents anti-inflammatoires, les agents anti-conception, les agents enzy- 50 matiques, les cellules, les facteurs de croissance, les agents antiviraux, les agents antibactériens, les agents anti- fongiques, les agents hypoglycémiques, les agents antihistaminiques, les agents chimiotactiques, les agents nu- traceutiques, les agents anti-obésité, les agents anti-tabagisme, les agents obstétriques et les agents antiasthma- tiques.

55 5. Système de fixation et de confinement de matrice biologique selon la revendication 4, dans lequel les agents pharmacologiquement actifs sont l’hydroxyapatite, la protéine morphogénétique osseuse, le VEGF ou leurs com- binaisons.

20 EP 1 528 894 B1

6. Système de fixation et de confinement de matrice biologique selon la revendication 1, dans lequel le dispositif de fixation est un ou plusieurs dispositifs choisis dans le groupe constitué par les agrafes, les cerclages, les vis, les plaques, les adhésifs, les liaisons et les sutures.

5 7. Système de fixation et de confinement de matrice biologique selon la revendication 1, dans lequel la gaine, les particules ou les deux comprennent en outre un ou plusieurs additifs biocompatibles.

8. Système de fixation et de confinement de matrice biologique selon la revendication 7, dans lequel le ou les additifs biocompatibles sont choisis dans le groupe constitué par les époxy, les polyesters, les acryliques, les nylons, les 10 silicones, le polyanhydride, le polyuréthane, le polycarbonate, le poly(tétrafluoroéthylène), la polycaprolactone, l’oxyde de polyéthylène, le polyéthylène glycol, le poly(chlorure de vinyle), l’acide polylactique, l’acide polyglycolique, l’oxyde de polypropylène, le poly(alkylène)glycol, le polyoxyéthylène, l’acide sébacique, l’alcool polyvinylique, le méthacrylate de 2-hydroxyéthyle, le polyméthacrylate de méthyle, le 1,3-bis(carboxyphénoxy)propane, les lipides, la phosphatidylcholine, les triglycérides, le polyhydroxybutyrate, le polyhydroxyvalérate, le poly(oxyde d’éthylène), 15 les polyorthoesters, les poly(acides aminés), les polycyanoacrylates, les polyphosphazènes, la polysulfone, la po- lyamine, les poly(amidoamines), la fibrine, le graphite, le fluoropolymère flexible, l’isopropylstyrène à base d’isobu- tyle, la vinylpyrrolidone, l’acétate et dibutyrate de cellulose, le caoutchouc de silicone et les copolymères de ceux-ci.

9. Système de fixation et de confinement de matrice biologique selon la revendication 1, dans lequel la totalité ou une 20 partie de la gaine et des particules est réticulée avec un ou plusieurs agents de réticulation.

10. Système de fixation et de confinement de matrice biologique selon la revendication 9, dans lequel le ou les agents de réticulation sont choisis dans le groupe constitué par le glutaraldéhyde, le p-azidobenzoylhydazide, le N-5-azido- 2-nitrobenzoyloxysuccinimide, le 6-[4’-azido-2’-nitro-phénylamino]hexanoate de N-succinimidyle et la 4-[p-azidosa- 25 licylamido]butylamine.

11. Système de fixation et de confinement de matrice biologique selon la revendication 1, dans lequel les particules ont une taille d’environ 10 nm à 5 mm.

30 12. Utilisation d’une ou de plusieurs protéines biocompatibles combinées avec un ou plusieurs solvants biocompatibles pour la fabrication d’un système de fixation et de confinement de matrice biologique selon la revendication 1.

13. Utilisation selon la revendication 12, dans laquelle ladite gaine a deux extrémités qui adhèrent l’une à l’autre avec un dispositif de fixation pour former une enceinte. 35 14. Utilisation selon la revendication 12, dans laquelle les protéines biocompatibles sont choisies dans le groupe cons- titué par l’élastine, le collagène, l’albumine, l’ovalbumine, la kératine, la fibronectine, la soie, la fibroïne de soie, l’actine, la myosine, le fibrinogène, la thrombine, l’aprotinine, l’antithrombine III, les blocs de type élastine, les blocs de type soie, les blocs de type collagène, les blocs de type laminine, les blocs de type fibronectine et les blocs de 40 type soie, de type élastine, le collagène-héparine, le collagène-élastine-albumine-héparine, le collagène-albumine, le collagène-élastine-héparine et le collagène-chondroïtine.

15. Utilisation selon la revendication 12, dans laquelle le solvant biocompatible est choisi dans le groupe constitué par l’eau, le diméthylsulfoxyde (DMSO), les alcools biocompatibles, les acides biocompatibles, les huiles et les glycols 45 biocompatibles.

16. Utilisation selon la revendication 12, dans laquelle la gaine comprend un ou plusieurs agents pharmacologiquement actifs et le ou les agents pharmacologiquement actifs sont choisis dans le groupe constitué par les analgésiques, les anesthésiques, les agents antipsychotiques, les facteurs de croissance angiogéniques, les agents biochimiques 50 de réparation osseuse, les stéroïdes, les antistéroïdes, les corticostéroïdes, les agents antiglaucomateux, les agents anti-alcool, les agents anticoagulants, les matières génétiques, les agents antithrombolytiques, les agents antican- céreux, les agents anti-Parkinson, les agents antiépileptiques, les agents anti-inflammatoires, les agents anti-con- ception, les agents enzymatiques, les cellules, les facteurs de croissance, les agents antiviraux, les agents anti- bactériens, les agents antifongiques, les agents hypoglycémiques, les agents antihistaminiques, les agents chimio- 55 tactiques, les agents nutraceutiques, les agents anti-obésité, les agents anti-tabagisme, les agents obstétriques et les agents antiasthmatiques.

17. Utilisation selon la revendication 16, dans laquelle les agents pharmacologiquement actifs sont l’hydroxyapatite, la

21 EP 1 528 894 B1

protéine morphogénétique osseuse, le VEGF ou leurs combinaisons.

18. Utilisation selon la revendication 12, dans laquelle le dispositif de fixation est un ou plusieurs dispositifs choisis dans le groupe constitué par les agrafes, les cerclages, les vis, les plaques, les adhésifs, les liaisons et les sutures. 5 19. Utilisation selon la revendication 12, comprenant en outre un ou plusieurs additifs biocompatibles.

20. Utilisation selon la revendication 19, dans laquelle le ou les additifs biocompatibles sont choisis dans le groupe constitué par les époxy, les polyesters, les acryliques, les nylons, les silicones, le polyanhydride, le polyuréthane, 10 le polycarbonate, le poly(tétrafluoroéthylène), la polycaprolactone, l’oxyde de polyéthylène, le polyéthylène glycol, le poly(chlorure de vinyle), l’acide polylactique, l’acide polyglycolique, l’oxyde de polypropylène, le poly(alkylène)gly- col, le polyoxyéthylène, l’acide sébacique, l’alcool polyvinylique, le méthacrylate de 2-hydroxyéthyle, le polymétha- crylate de méthyle, le 1,3-bis(carboxyphénoxy)propane, les lipides, la phosphatidylcholine, les triglycérides, le po- lyhydroxybutyrate, le polyhydroxyvalérate, le poly(oxyde d’éthylène), les polyorthoesters, les poly(acides aminés), 15 les polycyanoacrylates, les polyphosphazènes, la polysulfone, la polyamine, les poly(amidoamines), la fibrine, le graphite, le fluoropolymère flexible, l’isopropylstyrène à base d’isobutyle, la vinylpyrrolidone, l’acétate et dibutyrate de cellulose, le caoutchouc de silicone et les copolymères de ceux-ci.

21. Utilisation selon la revendication 12, comprenant en outre l’administration d’une pluralité de particules dans la gaine, 20 lesdits particules comprenant une ou plusieurs protéines biocompatibles combinées avec un ou plusieurs solvants biocompatibles et un ou plusieurs agents pharmacologiquement actifs.

22. Utilisation selon la revendication 21, dans laquelle les particules ont une taille d’environ 10 nm à 5 mm.

25 23. Utilisation selon la revendication 21, dans laquelle les protéines biocompatibles sont choisies dans le groupe cons- titué par l’élastine, le collagène, l’albumine, l’ovalbumine, la kératine, la fibronectine, la soie, la fibroïne de soie, l’actine, la myosine, le fibrinogène, la thrombine, l’aprotinine, l’antithrombine III, les blocs de type élastine, les blocs de type soie, les blocs de type collagène, les blocs de type laminine, les blocs de type fibronectine et les blocs de type soie, de type élastine, le collagène-héparine, le collagène-élastine-albumine-héparine, le collagène-albumine, 30 le collagène-élastine-héparine et le collagène-chondroïtine.

24. Utilisation selon la revendication 21, dans laquelle le solvant biocompatible est choisi dans le groupe constitué par l’eau, le diméthylsulfoxyde (DMSO), les alcools biocompatibles, les acides biocompatibles, les huiles et les glycols biocompatibles. 35 25. Utilisation selon la revendication 21, dans laquelle le ou les agents pharmacologiquement actifs sont choisis dans le groupe constitué par les analgésiques, les anesthésiques, les agents antipsychotiques, les facteurs de croissance angiogéniques, les agents biochimiques de réparation osseuse, les stéroïdes, les antistéroïdes, les corticostéroïdes, les agents antiglaucomateux, les agents anti-alcool, les agents anticoagulants, les matières génétiques, les agents 40 antithrombolytiques, les agents anticancéreux, les agents anti-Parkinson, les agents antiépileptiques, les agents anti-inflammatoires, les agents anti-conception, les agents enzymatiques, les cellules, les facteurs de croissance, les agents antiviraux, les agents antibactériens, les agents antifongiques, les agents hypoglycémiques, les agents antihistaminiques, les agents chimiotactiques, les agents nutraceutiques, les agents anti-obésité, les agents anti- tabagisme, les agents obstétriques et les agents antiasthmatiques. 45 26. Utilisation selon la revendication 25, dans laquelle les agents pharmacologiquement actifs sont l’hydroxyapatite, la protéine morphogénétique osseuse, le VEGF ou leurs combinaisons.

27. Utilisation selon la revendication 21, comprenant en outre un ou plusieurs additifs biocompatibles. 50 28. Utilisation selon la revendication 27, dans laquelle le ou les additifs biocompatibles sont choisis dans le groupe constitué par les époxy, les polyesters, les acryliques, les nylons, les silicones, le polyanhydride, le polyuréthane, le polycarbonate, le poly(tétrafluoroéthylène), la polycaprolactone, l’oxyde de polyéthylène, le polyéthylène glycol, le poly(chlorure de vinyle), l’acide polylactique, l’acide polyglycolique, l’oxyde de polypropylène, le poly(alkylène)gly- 55 col, le polyoxyéthylène, l’acide sébacique, l’alcool polyvinylique, le méthacrylate de 2-hydroxyéthyle, le polymétha- crylate de méthyle, le 1,3-bis(carboxyphénoxy)propane, les lipides, la phosphatidylcholine, les triglycérides, le po- lyhydroxybutyrate, le polyhydroxyvalérate, le poly(oxyde d’éthylène), les polyorthoesters, les poly(acides aminés), les polycyanoacrylates, les polyphosphazènes, la polysulfone, la polyamine, les poly(amidoamines), la fibrine, le

22 EP 1 528 894 B1

graphite, le fluoropolymère flexible, l’isopropylstyrène à base d’isobutyle, la vinylpyrrolidone, l’acétate et dibutyrate de cellulose, le caoutchouc de silicone et les copolymères de ceux-ci.

5

10

15

20

25

30

35

40

45

50

55

23 EP 1 528 894 B1

24 EP 1 528 894 B1

25 EP 1 528 894 B1

26 EP 1 528 894 B1

27 EP 1 528 894 B1

28 EP 1 528 894 B1

29 EP 1 528 894 B1

30 EP 1 528 894 B1

31 EP 1 528 894 B1

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

• EP 0082621 A [0006] • US 796170 A [0043] • US 6342250 B [0043] • US 37613602 P [0043]

Non-patent literature cited in the description

• FRANCO A. FERRARI ; JOSEPH CAPPELLO. Bi- • International Journal of Pharmaceutics, 1980, vol. 7, osynthesis of Protein Polymers, in: Protein-Based 63-75 [0031] Materials. Birkhauser, 1997, 37-60 [0029] • MAN et al. J. Invent. Dermatol., 1996, vol. 106 (5), • J. CAPPELLO et al. Biotechnol. Prog., 1990, vol. 6, 1096 [0031] 198 [0029] • Physicians’ Desk Reference®: PDR. Medical Eco- • International Journal of Pharmaceutics, 1994, vol. nomics, 1974 [0035] 111, 223-233 [0031]

32